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1 Introduction 
 
 
Chapter 1 
Introduction 
 
 
1.1 G protein coupled receptors  
 
G protein coupled receptors (GPCRs), also known as seven transmembrane (7TM) 
receptors, represent the largest protein superfamily of cell surface receptors involved 
in signal transduction. GPCRs are activated by an external signal in the form of a 
ligand or, in the case of rhodopsin, a photon. Both induce a conformational change in 
the receptor and, by this, the intracellular transduction of the signal via the G protein 
and second transmitters to subsequent pathways modulating cellular responses. 
GPCRs are found only in eukaryotes, including yeast, plants and choanoflagellates 
(King et al., 2003). They are extremely versatile receptors. About 800 different 
GPCRs in human respond to a wide variety of activating ligands: biogenic amines, 
purines and nucleic acid derivatives, lipids, peptides and proteins, organic odorants 
and pheromones, tastants, ions like calcium and protons, and even to photons 
(Jacoby et al., 2006). Just as diverse are the modulated physiological processes: 
neurotransmission, secretion, cellular metabolism, differentiation and growth, 
inflammatory and immune responses, taste and odor. Therefore, GPCRs represent 
the major target class (30% of all targets investigated so far) for the design of new 
drugs for pharmacological intervention. Around 30% of all marketed drugs act on 
GPCRs as agonists or antagonists, activating and blocking the receptor, respectively 
(Hebert and Bouvier, 1998). On the other hand, 40 to 50% of the current drug target 
are GPCRs (Drews, 2000; Jacoby et al., 2006). In the human genome project 
(Consortium, 2004) more than 800 genes (about 2% of the genome) have been 
identified that belong to the GPCR superfamily (Fredriksson and Schiöth, 2005), 
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most being orphan receptors having no as yet identified ligand. In conclusion, this 
class of proteins is historically the most successful therapeutic target family (Hopkins 
and Groom, 2002). 
To classify a protein as GPCR depends on two essential requirements: the first 
concerns the presence of seven sequence stretches of about 25 to 30 amino acids 
with a relatively high degree of hydrophobicity. These sequences form seven α-
helices, the so-called transmembrane (TM) domain, that span the plasma membrane 
in a counter-clockwise order when viewed from the extracellular side. The presence 
of extracellular and/or intra-TM ligand binding sites and sufficient conformational 
flexibility to swith from inactive to active states enable signal transduction from 
outside to inside the cell. The second principal requirement is the capability of the 
receptor to interact with a particular heterotrimeric G protein. However, the term 7TM 
receptor is more technically correct because the coupling with a G protein has not 
been demonstrated for a number of GPCRs whose genes have recently been 
sequenced (Fredriksson and Schiöth, 2003), and not all receptors that activate a G 
protein are members of the GPCR superfamily (e.g. receptors for epidermal growth 
factor, insulin, insulin-like growth factor-I and II ) (Iismaa et al., 1995; Kuemmerle and 
Murthy, 2001).  
 
1.1.1 GPCR classification 
 
Several approaches have been used to classify this superfamily, some of these are 
based on the native ligands, on phylogenetic analysis of the amino acid sequences, 
on clustering of the genes in the human genome and on physiological and structural 
features. One of the most frequently used systems used clans or classes to group 
the GPCRs.  Following this classification the GPCRs can be grouped into six classes 
based on sequence homology and functional similarity: A, B, C, D, E and F. 
Subclasses are assigned by roman numbers (Attwood and Findlay, 1994; Foord et 
al., 2005; http://www.ebi.ac.uk/interpro/ISearch?query=gpcr; Kolakowski, 1994). 
These classes try to cover all GPCRs in vertebrates and invertebrates (Table 1.1).  
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         Table 1.1: Classification of GPCRs in vertebrates and invertebrates  
 
Class A   (Rhodopsin-like) 
 I Chemokine receptor, GPR137B 
 II Chemokine , Interleukin-8, Adrenomedullin receptors,   Duffy blood group, chemokine receptorG,  Protein-coupled Receptor 30 
 III Angiotensin II , Bradykinin receptor , GPR15, 25 
 IV Opioid , Somatostatin ,  neuropeptide,  orphan , DEZ orphan receptors,  GPR1 
 V Galanin , Cysteinyl leukotriene, Leukotriene B4 , Relaxin , KiSS1-derived peptide , Melanin-concentrating hormone 1Urotensin-II receptors 
 VI GPR40-related , P2 purinoceptor, GPR31, 81, 82, 109B, Oxoglutarate (alpha-ketoglutarate) receptor 1, Succinate receptor 1 
 VII 
P2 purinoceptor, Protease-activated receptor, Epstein-Barr virus induced gene 2 
(lymphocyte-specific G protein-coupled receptor), GPR4, 17, 18, 20, 23, 35, 55, 65, 68, 
132, Coagulation factor II receptor 
 VIII P2 purinoceptor, GPR34, 87, 171, Platelet-activating factor receptor 
 IX Cannabinoid , Lysophosphatidic acid , Sphingosine 1-phosphate, Melanocortin/ACTH receptors, GPR3, 6, 12 
 X Opsins 
 XI Eicosanoid receptor 
 XII Cholecystokinin , Neuropeptide FF , Orexin, Vasopressin r, Gonadotrophin releasing hormone receptors, GPR22, 103, 176 
 XIII Melatonin, Neurokinin, Neuropeptide Y, Prolactin-releasing peptide, Prokineticin receptors, 1GPR19, 50, 75, 83 
 XIV Bombesin, Endothelin , Neuromedin U, Neurotensin r, Thyrotropin-releasing hormone, Growth hormone secretagogue, Motilin receptors,GPR39 
 XV 5-Hydroxytryptamine (5-HT2,6), Adrenergic, Dopamine, OctopamineTrace amine, Histamine H2 receptors 
 XVI Histamine H1,3,4, Adenosine, Muscarinic acetylcholine receptors, GPR21, 45, 52, 61, 62, 63, 78, 84, 85, 88, 101, 161, 173 
 XVII 5-Hydroxytryptamine (5-HT1,4,5A,7) receptor 
 XVIII Anaphylatoxin, Formyl peptide receptors, MAS1 oncogene, GPR1, 32, 44, 77 
 XIX Glycoprotein hormone receptor, Leucine-rich repeat-containing G protein-coupled receptor 4 
Class B   (Secretin receptor family) 
 I 
Adenylate cyclase-activating type 1, pituitary, Calcitonin, Corticotropin-releasing 
hormone, Glucagon receptor-related, Growth hormone releasing hormone, Parathyroid 
hormone, Secretin, Vasoactive intestinal peptide receptors 
 II 
  
Brain-specific angiogenesis inhibitor, CD97 antigen, EMR hormone, Gastric inhibitory 
polypeptide, GPR56 orphan, Latrophilin, Diuretic hormone receptors 
Class C   (Metabotropic glutamate/pherormone) 
 I mGluR1mGluR5 
 II mGluR2mGluR3 
 III mGluR4mGluR6mGluR7mGluR8 
Class D   (Fungal mating pherormone receptor) 
Class E    (Cyclic AMP receptor) 
Class F   (Frizzled/Smoothened) 
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Some families in this A-F classification do not exist in human. For example, clans D 
and E are fungal pheromone and cAMP receptors, and clan F contains 
archaebacterial opsins. In general the mammalian GPCRs have been grouped into 
three classes, A, B and C (Kolakowski, 1994) excluding the subfamily IV in clan A 
comprising invertebrate opsin receptors. 
 
1.1.2 Signal transduction mechanisms in GPCRs 
 
Signal transduction at the cellular level refers to the transmission of signals from 
outside the cell to inside. In general this process can be simple but for GPCRs a 
more complex signal transduction pathway involves the coupling of ligand-receptor 
interactions to many intracellular events. Binding of an agonist induces or stabilizes 
an active receptor state, resulting in increased affinity for the G-protein located at the 
cytosolic side of the plasma membrane.  
The G-proteins are composed of α, β and γ subunits, β and γ are tightly associated 
and can be considered as one functional unit. There are many classes of 
heterotrimeric G-proteins involved in signal transduction. At least 28 distinct G-
protein α, 5 β and 12 γ subunits have been identified and subdivided into 4 families 
based on the degree of primary sequence similarities of the α subunit (Figure 1.1).  
Mutagenesis and biochemical experiments suggest that receptor activation by an 
agonist affects the conformation of intacellular loops and thus uncovers previously 
masked binding sites for the G-protein. This leads to a rapid release of GDP from the 
α subunit (Figure 1.2) (Hamm, 1998; Sprang, 1997). Under physiological conditions 
GDP is immediately replaced by GTP. The nucleotide exchange reduces the affinity 
of the α subunit for the βγ complex and causes the dissociation of the heterotrimer 
into Gα-GTP and Gβγ. The Gα-GTP subunit activates (Gαs, Gαq, Gα12) or inhibits (Gαi) 
effector proteins such as adenylyl cyclases 1-9, phospholipases A2 and C β1-4, 
phosphodiesterase (PDE) and ion channels (for details, see Figure 1.2). This 
activation leads to the production of second messengers like cyclic 3’,5’-adenosine 
monophosphate (cAMP), diacylglycerol (Adams et al.), or to the modulation of 
inositol-1,4,5-triphosphate (IP3).  
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Figure 1.1: G-proteins: role in signal transduction and classification   
 
These second messengers can induce changes in the intracellular ion concentration, 
regulate enzyme activity (especially protein kinases), modulate transcription factors, 
activate or inhibit gene expression and other fast cellular responses. All these effects 
described above are induced by de Gα subunit. It is however also known that the Gβγ 
heterodimer can play an active role in the signal transduction in animal cells 
(Clapham and Neer, 1993; Sternweis, 1994), e.g. in the regulation of K+ channels, of 
phospholipase Cβ and of certain isoforms of adenylyl cyclase. The activated state of 
the Gα-GTP subunit lasts until GTP is hydrolysed by the slow GTPase activity of Gα. 
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This hydrolysis induces the re-association between Gα and Gβγ for the restart of a 
new cycle.  
 
 
Figure 1.2: GPCR activation and deactivation cycle after stimulus by an agonist. 
 
An omnipresent property of signalling through GPCRs is their desensitization when 
they are exposed to an agonist or partial agonist for a prolonged period of time. 
Typically, activation of a GPCR leads to a) activation and inhibition of specific signal 
pathways in the cell, b) short term desensitization mediated by phosphorylation of 
GPCRs by G protein-coupled receptor kinases (GRK) followed by β-arrestin binding 
to GPCRs that uncouple the receptor from the G-protein, and c) endocytosis of the 
receptor followed by postendocytotic sorting of the receptor, either back d) to the 
plasma membrane or e) to lysosomes for degradation. In general, for many GPCRs, 
prolonged exposure to agonists or partial agonists results in down-regulation, 
prolonged exposure to antagonists in receptor supersensivity (e.g., down-regulation 
of 5-HT2A and 5-HT2C receptors is produced by a chronic administration of 5-HT2 
agonists, however, in this case and uniquely among biogenic amine receptors, also 
by antagonists). The key reaction of this down-regulation is the phosphorylation of 
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the cytoplasmic receptor domain by protein kinases. There are two kinds of 
desensitization: 1) homologous desensitization, in which the activated GPCR is 
down-regulated; and 2) heterologous desensitization, where the activated GPCR 
causes down-regulation of a different GPCR. In the first case, agonist binding to the 
GPCR leads to GRK-mediated phosphorylation of the receptor. For the second 
mechanism, agonist occupancy of the target is not required; the second messenger, 
produced by activation of one GPCR, induces activation of protein kinases that could 
phosphorylate another GPCR target at the plasma membrane.  
Another feature that characterizes GPCRs is constitutive activity which occurs from 
case to case. Until now, it has been observed in more than 60 wild-type GPCRs, and 
a large number of disease-causing GPCR mutants with increased constitutive activity 
has been identified. This property can be defined as the ability of a GPCR to adopt 
spontaneously (in absence agonists or antagonists) an active conformation that 
activates G-proteins (Lefkowitz et al., 1993; Samama et al., 1993; Seifert and 
Wenzel-Seifert, 2002).  
 
1.2 Serotonin (5-hydroxytryptamine, 5-HT) 
 
1.2.1 Historical overview 
 
Serotonin is a monoamine neurotransmitter widely distributed in animals and plants, 
occurring in vertebrates, fruits, nuts and venoms. The synthesis in animals and 
human happens in serotonergic neurons in the central nervous system (CNS), blood 
platelets and enterochromaffine cells in the gastrointestinal tract. The discovery of 
serotonin can be attributed to an Italian pharmacologist, Dr. Vittorio Erspamer, who 
was looking for substances capable of causing smooth muscle contraction and who 
identified such a substance in an acetone extract of rabbit gastric mucosa in the 
1930’s (Erspamer and Asero, 1952, 1953). He named this substance enteramine. In 
the late 1940’s the laboratory of Dr Irving Page isolated, partially purified and 
crystallised a vasoconstricting substance in serum and named it serotonin (Rapport 
et al., 1948). The structure was reported in 1949. Around 1952 it was realized that 
enteramine and serotonin were the same substance. It was initially recognised as 
powerful vasoconstrictor in blood serum, but after chemical identification other 
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physiological functions, especially in the CNS, were elucidated. In 1952 Dr. Betty 
Twarog joined the Page lab to test the idea that invertebrate neurotransmitters may 
similarly act in vertebrates. Her research resulted in the identification of serotonin in 
the brain (Twarog and Page, 1953). Afterwards the function as human 
neurotransmitter was suggested (Brodie and Shore, 1957).  
Serotonin is associated with a broad range of actions in the human body, including 
the control of appetite, sleep, memory and learning, temperature regulation, effects 
on mood, behaviour, cardiovascular function, muscle contraction, endocrine 
regulation and depression. Subsequent to his discovery of serotonin, Page commen-
ted that no other physiological substance known performs such diverse actions in the 
body. A number of serotonin congeners are also present in nature and have been 
shown to possess a variety of peripheral and CNS activities. 
Corresponding to these manifold actions of serotonin, but also to the large number 
and different localization of 5-HT receptor subtypes (see below), aberrations in the 
serotoninergic system including biosynthesis and metabolism of the neurotransmitter 
lead to malfunctions in the regulation of many psychophysiological processes. 
Accordingly, psychiatric disorders such as anxiety, depression, aggressiveness, 
panic, obsessive-compulsive disorders, schizophrenia, suicidal behaviour and 
autism, neurodegenerative disorders as Alzheimer’s disease, Parkinsonism, and 
Huntington’s chorea, migraine, emesis and alcoholism may result. Therefore, various 
drugs act on the 5-HT system, including some antidepressants, anxiolytics, 
antiemetics, antipsychotics and anti-migraine agents. 
 
1.2.2 Biosynthesis and metabolism 
 
Serotonin is ingested from various dietary sources but is also synthesized in a two-
steps metabolic pathway from the essential amino acid tryptophan (Figure 1.3).  
Tryptophan hydroxylase, the rate-limiting enzyme, firstly converts tryptophan to 5-
hydroxytryptophan, which is then decarboxylated by L-aromatic animo acid 
decarboxylase, a widely distributed enzyme with a broad substrate specificity. 
Prerequisite of the synthesis in the brain is the active transport of ingested 
tryptophan, performed by a carrier that also transports other bulky neutral amino 
acids. Therefore the tryptophan level in the brain is influenced not only by its own 
plasma concentration but also by the plasma levels of amino acids competing for the 
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brain uptake carrier. The principal route of serotonin inactivation involves monoamine 
oxydase forming 5-hydroxyindoleacetaldehyde which is then converted into 5-
hydroxyindoleacetic acid by an ubiquitous enzyme, aldehyde dehydrogenase. The 
acid is transported out of the brain and eliminated through excretion in the urine. 
Other pathways of metabolism have been suggested. One of these, shown in Figure 
1.3, involves the enzyme sulfatransferase causing, by sulfatation, the formation of 
tryptamine-O-sufate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                        Figure 1.3: Catalytic mechanisms in serotonin metabolism.  
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1.3 Serotonin receptors (5-HTR) 
 
5-HT receptors (5-HTR) are receptors for the neurotransmitter and peripheral signal 
mediator serotonin as endogenous agonist. They are located in the cell membrane of 
neurons and other cell types, including smooth muscle cells, in animals. In the intact 
brain the function of many 5-HTRs (see classification below) is associated with 
specific physiological responses, ranging from modulation of the neuronal activity 
and transmitter release to behavioural changes. Individual 5-HTR subtypes affect the 
release of other neurotransmitters such as glutamate, dopamine and GABA. At the 
molecular level, 5-HTRs are members of the 7TM type and, with exception of the 5-
HT3R subtype that is a ligand-gated ion channel, belong to the GPCR superfamily.  
1.3.1 5-HTR classification 
 
Evidence of the existence of 5-HT receptors was first presented in 1957 by Gaddum 
and Picarelli, who experimented with the isolated guinea pig ileum (Gaddum and 
Picarelli, 1957). They described two types of receptors affecting muscle contraction: 
D receptors blocked by dibenzyline and M receptors blocked by morphine. In 1970’s, 
the ligand binding sites were tentatively explored using [3H]5-HT, and it was shown 
that [3H]LSD binding can be displaced by 5-HT (Farrow and Van Vunakis, 1972; 
Marchbanks, 1966, 1967). In the same decade also the earliest evidence for a 
selective high-affinity and saturable binding of [3H]5-HT was published (Bennett and 
Snyder, 1975, 1976). The discrimination of two classes of 5-HT receptors, 5-HT1R 
and 5-HT2R, labeled with high affinity by [3H]5-HT and [3H]spiperone, respectively, 
was based on the discovery that [3H]spiroperidol could also selectively label the 
suggested 5-HT1R subtype (Leysen et al., 1978; Peroutka and Snyder, 1979). 
Additionally, 5-HT1Rs appeared to be heterogeneous, because the inhibition of [3H]5-
HT binding by spiroperidol was biphasic. Pedigo indicated the existence of two 
subtypes labelled by [3H]5-HT: 5-HT1AR (high affinity for spiperidol) and 5-HT1BR (low 
affinity for spiperidol). A third 5-HT1R species, 5-HT1CR, was then proposed on the 
basis of the high affinity displacement of [3H]5-HT by mesulergide (Pazos et al., 
1985b; Pedigo et al., 1981).  
After functional studies, performed to attribute a physiological role to these binding 
sites, it became necessary to reclassify the 5-HT receptors. A group of scientists 
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proposed three major classes: 5-HT1R-like (heterogeneous group of receptors with 
high affinity for 5-HT and methiothepin as selective antagonist), 5-HT2R (D receptors 
described above, mediating a variety of peripheral actions of 5-HT) and 5-HT3R (M 
receptors, present in peripheral neurons and mediating the depolarizing actions of 5-
HT) (Bradley et al., 1986). This classification was later slightly modified (Peroutka, 
1990) because of the detection of a new 5-HT1R subtype, called 5-HT1DR (Heuring 
and Peroutka, 1987), the pharmacological and molecular similarity of 5-HT1CR and 5-
HT2R (Hartig, 1989a), and the verification of the functional role of 5-HT1R-like 
receptors. In conclusion, three classes were proposed: 5-HT1R (5-HT1AR, 5-HT1BR 
and 5-HT1DR), 5-HT2R (5-HT2AR, 5-HT2BR, 5-HT1CR) and 5-HT3R. However, this 
classification based on agonist and antagonist selectivities did not account for some 
specific sites characterized by binding, functional properties or individual pharmaco-
logical profiles (e.g., the 5-HT4R). In 1989 a new and simplified classification was 
proposed (Hartig, 1989a) based on sequence homology, structural considerations 
from molecular biology and the signal transduction pathways. Moreover, the 
application of molecular biology techniques has led to the discovery of addtitonal 5-
HTR subtypes (Boess and Martin, 1994; Peroutka, 1994). Now 5-HTR are assigned 
to one of seven families, 5-HT1-7, comprising a total of 14 structurally and 
pharmacologically distinct subtypes (Hoyer et al., 1994) (Table 1.2). 
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Table 1.2: Classification of 5-HT receptors 
Receptor 
subtype Agonists Antagonists Expression 
Transduction 
mechanism Action 
      
5-HT1A Buspirone, psilocin, LSD 
 
spiperone, 
methiothepin, 
ergotamine, 
yohimbine 
 
CNS, myenteric 
plexus 
Gi/Go CNS: neuronal 
inhibition, 
behavioural effects 
(sleep, feeding, 
thermoregulation, 
aggression, 
anxiety) 
5-HT1B Ergotamine, sumatriptan 
 
Methiothepin, 
yohimbine, 
metergoline, 
Risperidone 
CNS, vascular 
smooth muscle, 
automatic 
terminals 
Gi/Go CNS: presynaptic 
inhibition, 
behavioural effects, 
vascular: 
pulmonary 
vasoconstriction 
5-HT1D 5-(Nonyloxy)tryptamine, 
sumatriptan 
Methiothepin, 
yohimbine, 
metergoline, 
ergotamine 
CNS, vascular 
smooth muscle; 
sympathoinhibition
in automatic 
neurones 
Gi/Go CNS: locomotion, 
anxiety; vascular: 
cerebral 
vasoconstriction 
5-HT1E   CNS Gi/Go  
5-HT1F   CNS, uterus, 
mesentery 
Gi/Go  
5-HT2A α-methyl-5-HT, LSD, 
psilocin, DOI 
 
Nefazodone, 
trazodone, 
mirtazapine, 
ketanserin, 
cyproheptadine, 
pizotifen, 
atypical 
antipsychotics 
 
CNS, 
gastrointestinal 
tract, vascular and 
bronchial smooth 
muscle, vascular 
endothelium, 
patelets 
Gq/G11 CNS: neuronal 
excitation, 
behavioural effects, 
learning, anxiety; 
smooth muscle: 
contraction, 
vasoconstriction / 
vasodilatation; 
platelets: 
aggregation 
5-HT2B α-methyl-5-HT, LSD, DOI, 
Fenfluramine 
 
yohimbine Smooth muscle of 
ileum, stomac 
fundus, uterus 
vascular 
endothelium 
Gq/G11 stomach: 
contraction 
5-HT2C α-methyl-5-HT, 
agomelatine, LSD, 
psilocin, DOI 
mesulergine, 
agomelatine, 
fluoxetine, 
methysergide 
CNS Gq/G11 CNS: anxiety, 
choroid plexus: 
cerebrospinal fluid 
(CSF) secretion 
5-HT3 2-methyl-5-HT metoclopramide 
(high doses), 
renzapride, 
ondansetron, 
alosetron, 
mirtazapine, 
memantine 
CNS, post-
ganglionic 
sympathetic, 
sensory neurones 
Intrinsic 
transmitter-gated 
ion channel 
CNS, PNS: 
neuronal excitation, 
anxiety, emesis 
5-HT4 5-methoxytryptamine, 
metoclopramide, 
renzapride, tegaserod, RS 
67333 
GR113808 
Piboserod 
CNS, cardiac 
muscle, 
oesophageal and 
vascular smooth 
muscle, myenteric 
plexus 
GS GIT: 
gastrointestinal 
motility; CNS: 
neuronal excitation, 
learning, memory 
5-HT5A 5-carboxytryptamine, LSD Unknown CNS GS CNS (cortex, 
hippocampus, 
cerebellum): 
unknown 
5-HT6 LSD SB271046 [5] CNS Not defined CNS: unknown 
5-HT7 5-carboxytryptamine, LSD Methiothepin, 
risperidone 
CNS, superior 
cervical ganglion 
GS CNS, GIT, blood 
vessels: unknown 
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1.4 5-HT2 receptors (5-HT2R)  
 
5-HT2 receptors belong to the GPCR class A or 1 (rhodopsin-like), subclass XV; 
currently three subtypes are identified, 5-HT2AR (formerly 5-HT2R), 5-HT2BR (formerly 
5-HT2FR) and 5-HT2CR (formerly 5-HT1CR) which are similar in sequence, pharma-
cology and signal transduction pathways. The 5-HT2AR is expressed in the brain and 
in the periphery, the 5-HT2BR in the rat and mouse stomach fundus, in human in most 
peripheral organs and low-level in brain tissue and blood cells (Schmuck et al., 
1994), and the 5-HT2CR in the brain and the choroid plexus. The average amino 
acids identity between the three subtypes is 45-67% for the full-length receptor and 
68-79% for the transmembrane segments (Nelson, 1993). 5-HT2Rs are structurally 
quite distinct from other 5-HTR subtypes (Baxter et al., 1995). Phylogenetic analysis 
of class A aminergic GPCRs (Vassilatis et al., 2003) indicate that the whole serotonin 
group is considerably heterogeneous (Figure1.4). The 5-HT4R is more related to the 
histamine H2R than to the 5-HT1R subtypes which, together with 5-HT7R, are more 
closely connected with dopamine D2, D3 and D4 receptors than with 5-HT2R species 
and 5-HT6Rs. Within the 5-HT2R subfamily, 5-HT2ARs and 5-HT2CRs cluster together 
and differ from 5-HT2BRs.  
The 5-HT2R genes are characterized by the presence of two (5-HT2AR and 5-HT2BR) 
or three (5-HT2CR) introns in the coding sequence (Chen et al., 1992; Stam et al., 
1992b; Yu et al., 1991). 5-HT2Rs are coupled to Gq, activate phospholipase C and 
mobilize intracellular calcium, mediating a large number of central and peripheral 
physiologic functions of serotonin. Cardiovascular effects include contraction of blood 
vessels and shape changes of platelets. In the CNS, e.g., neuronal sensitization after 
tactile stimuli and hallucinogenic effects arise. The development of selective 
antagonists for each receptor subtype is now at an advanced stage. They are used 
as drugs or are candidates for the treatment of various CNS disorders including 
schizophrenia, anxiety, sleep, feeding disorders and migraine.  
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 0.1 
 
Figure 1.4 Phylogenetic tree of class A or 1 aminergic GPCRs. Red lines and black lines correspond 
to receptors with unknown ligands (orphan receptors) and known ligands, respectively. Adapted from 
Vassilatis et al., 2003. The line on the bottom indicates the horizontal distance equal to 10% sequence 
divergence.  
1.4.1 5-HT2A receptor 
 
The 5-HT2AR was initially detected in rat cortical membranes as high affinity binding 
site for [3H]spiperone with relatively low (micromolar) affinity for 5-HT, but a 
pharmacological profile of a 5-HT receptor (Leysen et al., 1978; Peroutka and 
Snyder, 1979). This receptor was originally defined as 5-HT2R, but later reassigned 
to the 5-HT receptor classification as 5-HT2AR. It is the main excitatory receptor 
subtype among the GPCRs for serotonin, although 5-HT2ARs may also have inhibi-
tory effects on certain brain areas such as the visual and the orbitofrontal cortex. The 
5-HT2AR  was first considered as target of psychedelic drugs like LSD, but later it was 
also found to mediate the action of antipsychotic drugs, especially the atypical ones. 
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1.4.1.1 5-HT2A receptor structure 
 
Until now, the 5-HT2AR of nine different species has been cloned: canine 
(Bonaventure et al., 2005; Masuda et al., 2004), guinea pig (Watts et al., 1994), 
Chinese hamster (Chambard et al., 1990), fruit fly (Adams et al., 2000), human 
(Saltzman et al., 1991; Stam et al., 1992a), Macaca mulatta (Johnson et al., 1995), 
mouse (Yang et al., 1992), pig (Johnson et al., 1995), rat (Julius et al., 1990). The 
nucleotide sequences of bovine and orangutan were submitted to the 
EMBL/GenBank/DDBJ database in 2003 by Tahara K. et al. and by Kitano T. et al. in 
2000, respectively. The intronless gene encodes for 471 (Chinese hamster, macaca 
mulatta, mouse, orangutan, human and rat) or 470 (bovine, dog and pig) amino 
acids. The human 5-HT2AR is located on chromosome 13q14-q21, consists of three 
exons separated by two introns, and spans over 20 Kb (Chen et al., 1992). It has a 
relatively high sequence identity with the human 5-HT2CR (c.a. 80% in the 7TM 
regions). The human 5-HT2AR is also 87% homologous with its rat counterpart with 
the highest amino acid identity (98%) within the 7TM domain. The regions of largest 
amino acid divergence between the rat and human receptors were at the N-terminal 
extracellular domain (75% homology) and the C-terminal intracellular domain (67% 
homology) (Figure 1.5). 
5-HT receptors share a conserved topological structure within the lipid bilayer which 
is also present in all other GPCRs. Specific domains have been shown to be 
functional determinants. The structure of the 5-HT2AR (Figure 1.6) can be divided into 
three domains:  
1. the extracellular domain which includes the amino terminus (NT) and the 
extracellular loops E1, E2 and E3 between transmembrane helices TM 2 and 
3, TM 4 and 5, and TM 6 and 7, respectively;  
2. the membrane domain consisting of seven membrane spanning helical 
regions TM1 – TM7;  
3. the intracellular domain which includes the carboxy terminus (Adams et al.) 
and the intracellular loops I1, I2 and I3 between TM 1 and 2, TM 3 and 4, and 
TM 5 and 6, respectively. 
A disulfide bond that is highly conserved in all GPCRs connects the extracellular end 
of TM3 with E2.  
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h5HT2A MDILCEENTSLSSTTNSLMQLNDDTRLYSNDFNSGEANTSDAFNWTVDSENRTNLSCEGC 60
r5HT2A MEILCEDNISLSSIPNSLMQLGDGPRLYHNDFNSRDANTSEASNWTIDAENRTNLSCEGY 60      
h5HT2A LSPSCLSLLHLQEKNWSALLTAVVIILTIAGNILVIMAVSLEKKLQNATNYFLMSLAIAD 120
r5HT2A LPPTCLSILHLQEKNWSALLTTVVIILTIAGNILVIMAVSLEKKLQNATNYFLMSLAIAD 120  
h5HT2A MLLGFLVMPVSMLTILYGYRWPLPSKLCAVWIYLDVLFSTASIMHLCAISLDRYVAIQNP 180
r5HT2A MLLGFLVMPVSMLTILYGYRWPLPSKLCAIWIYLDVLFSTASIMHLCAISLDRYVAIQNP 180     
h5HT2A IHHSRFNSRTKAFLKIIAVWTISVGISMPIPVFGLQDDSKVFKEGSCLLADDNFVLIGSF 240
r5HT2A IHHSRFNSRTKAFLKIIAVWTISVGISMPIPVFGLQDDSKVFKEGSCLLADDNFVLIGSF 240     
h5HT2A VSFFIPLTIMVITYFLTIKSLQKEATLCVSDLGTRAKLASFSFLPQSSLSSEKLFQRSIH 300
r5HT2A VAFFIPLTIMVITYFLTIKSLQKEATLCVSDLSTRAKLASFSFLPQSSLSSEKLFQRSIH 300     
h5HT2A REPGSYTGRRTMQSISNEQKACKVLGIVFFLFVVMWCPFFITNIMAVICKESCNEDVIGA 360
r5HT2A REPGSYAGRRTMQSISNEQKACKVLGIVFFLFVVMWCPFFITNIMAVICKESCNENVIGA 360     
h5HT2A LLNVFVWIGYLSSAVNPLVYTLFNKTYRSAFSRYIQCQYKENKKPLQLILVNTIPALAYK 420
r5HT2A LLNVFVWIGYLSSAVNPLVYTLFNKTYRSAFSRYIQCQYKENRKPLQLILVNTIPALAYK 420     
h5HT2A SSQLQMGQKKNSKQDAKTTDNDCSMVALGKQHSEEASKDNSDGVNEKVSCV 471
r5HT2A SSQLQVGQKKNSQEDAEQTVDDCSMVTLGKQQSEENCTDNIETVNEKVSCV 471        
TM1
TM2
TM4
TM3
TM5
TM6
TM7
 
Figure 1.5: Alignment of the sequences of human (h5HT2AR) and rat (r5HT2AR) receptors. Identical 
amino acids are in bold, non-identical in italics, and the TM regions TM1-TM7 are indicated with bars. 
 
As it is observed for all GPCRs, the 5-HT2AR is subject to post-translational 
modification and regulatory mechanisms. The N-terminal extracellular region 
contains glycosylation sites where complex sugar moieties bind to the receptor. The 
sugar groups play a role in processing the receptor to the cytoplasmic membrane, 
but apparently do not participate in ligand recognition or in functional mechanisms, 
for example, deletion of the N-terminus does not affect the receptor’s biological 
response to the endogenous ligand (Buck et al., 1991; Rands et al., 1990). The C-
terminal intracellular region is believed to play an important role in the desensitization 
of GPCRs via phosphorylation. The 5HT2AR is known to be desensitized by various 
selective agonists, presumably through a common phosphorylation mechanism 
(Hausdorff et al., 1990). The C-terminal intracellular regions of the human and rat 
5HT2AR contain a total of 14 serine/threonine residues that represent possible 
phosphorylation sites, 11 of which are conserved. A C-terminal cysteine residue at 
position 397 of the rat 5-HT2AR has been found to be essential for receptor activity 
(Buck et al., 1991). This residue is conserved in a variety of GPCRs and is believed 
to play a role in G-protein coupling (O'Dowd et al., 1988). 
Chapter 1: Introduction 
 
 
 
17
 
Figure 1.6: Snake plot of the human 5-HT2AR adapted from the GPCR database 
(http://www.gpcr.org/). The disulfide bond between Cys-148 and Cys-227 is represented by a yellow 
line. The colours encode residue properties (polar, neutral or charged, hydrophobic, aromatic or 
aliphatic). Parts of the sequence were deleted to avoid long loops (represented by "...").    
 
Analyses of aligned GPCRs identified residues highly conserved in subfamilies. 
These amino acids are probably involved in ligand binding or play a specific 
functional role as stabilization of receptor states by intramolecular contacts or 
interaction with G proteins.. This hypothesis has been confirmed by mutagenesis 
experiments. For 5-HT2A receptors the residues involved in the binding of ligands are 
localized in the extracellular side of TM3, TM5, TM6 and TM7. As indicated by the 
properties of receptor mutants, the binding site of the human 5-HT2AR is composed of 
Asp1553.32, Ser1593.36, Ser2395.43, Ser2425.46 that are possibly involved in polar 
interactions with ligands, Phe2405.44, Phe2435.47, Phe2445.48, Phe3396.51, Phe3406.52, 
Trp3366.68, Trp3677.40 and Tyr3707.43 that form two hydrophobic pockets surrounding 
the ligands.  
Certain residues in the second extracellular loop (E2) may also be important for the 
binding of agonists and antagonists. A direct contact between ligands and E2 is 
possible, especially close to the disulfide bridge formed between a cysteine in E2 and 
another one near the N-terminus of TM3, which anchors the E2 loop in proximity to 
the ligand binding site 
An important structural motif in all GPCRs is represented by the highly conserved 
triad DRY in the cytoplasmatic part of TM3 (Asp1723.49, Arg1733.50 and Tyr1743.51 in 
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the 5-HT2AR). Arg173 forms salt bridges with Asp1723.49 and with Glu3186.30, a highly 
conserved residue in the cytoplasmatic part of TM6. This so-called “ionic lock” is 
known to be responsible for the stabilization of the inactive receptor state. 
Conformational rearrangement of TM3 and TM6 after agonist binding involves 
cleavage of the ionic lock and activation of the receptor (Farrens et al., 1996; Gether 
et al., 1997; Rasmussen et al., 1999). 
 
1.4.1.2 5-HT2AR distribution, signal transduction and pharmacology  
 
5-HT2ARs can be found in the CNS, gastrointestinal tract, vascular and bronchial 
smooth muscles, vascular endothelium and platelets. The CNS distribution has been 
extensively mapped by receptor autoradiography, in situ hybridization and immuno-
cytochemistry. The autoradiography studies using [3H]spiperone, [3H]ketanserin, 
[125I]DOI and [3H]MDL 100907 as radioligands indicated high levels of 5-HT2A binding 
sites in particular cortical areas (neocortex, entorhinal and pyriform cortex and 
claustrum), in the caudate nucleus, nucleus occumbens, olfactory tubercle and 
hippocampus (López-Giménez et al., 1997; Pazos et al., 1985) where they are 
postsynaptically located in the 5-HT neurons and regulate dopamine, adrenaline, 
GABA, and glutamate neurotransmission (Hoyer et al., 2002). The functions of 5-
HT2ARs are based on the receptor localization and affect different tissues. The 
activation of the receptor by the endogenous neurotransmitter serotonin or with an 
agonist includes: 
 
• neural excitation, behavioural effects, learning and anxiety in the CNS. 
• contraction when the gastrointestinal tract and bronchial smooth 
muscles are considered 
•  vasoconstriction or vasodilatation in vascular smooth muscles  
• platelet aggregation.  
 
5-HT2ARs  are coupled to the Gαq/Gα11 signal transduction pathway. After receptor 
stimulation and activation with an agonist, Gαq/Gα11 and βγ subunits dissociate to 
initiate downstream effector pathways (Figure 1.7). The α subunit activates 
phospholipase C (PLC), which subsequently promotes the release of diacylglycerol 
(DAG) (Adams et al.) and inositol triphosphate (IP3). IP3 stimulates Ca2+ release from 
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the endoplasmatic reticulum, leading together with DAG to the activation of protein 
kinase C (PKC) (Urban et al., 2007).  
 
 
Figure 1.7: 5-HT2AR signal transduction. Agonist binding activates the 5-HT2AR, which in turn 
activates Gαq/G11. The α subunit activates PLC which cleaves PIP2 into IP3 and DAG. IP3 interacts with 
a calcium channel in the endoplasmatic reticulum (ER), releasing Ca2+ into the cytoplasm. The 
increase in Ca2+ level activates PKC, which translocates to the membrane, anchoring DAG and 
phosphatidylserine. 
 
The 5-HT2 receptor subfamily is characterized by a low affinity for the endogenous 
ligand (5HT), a high affinity for the agonist DOI and its structural analogs DOB and 
DOM, and high affinity for various receptor antagonists such as metergoline, 
ritanserin and IC 170809. Until recently, it was difficult to discriminate between the 5-
HT2 subtypes, even though ketanserin and spiperone are about two orders of 
magnitude more affine for 5-HT2AR than for 5-HT2BR and 5-HT2CR. However, these 
ligands do also bind to other monoamine receptors. With the development of 
selective antagonists it is now possible to discriminate the 5-HT2R subtypes in more 
detail by pharmacological in vitro and in vivo models (Baxter et al., 1995). MDL 
100907 is a potent and selective antagonist at 5-HT2AR with low affinity for 5-HT2CR 
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and other receptors. The discrimination of 5-HT2A, 5-HT2C and 5-HT2C receptors was 
also advanced by the recent design of potent antagonists with selectivity for the 5-
HT2BR, SB 204741, and for the 5-HT2CR, SB 242084 and RS-102221 (Baxter, 1996; 
Baxter et al., 1995; Bonhaus et al., 1997; Kennett et al., 1996a; Kennett et al., 1997a; 
Kennett et al., 1996b; Kennett et al., 1997b). The most selective 5-HT2AR ligands are 
ketanserin and MDL 100907. Antagonists such as risperidone, ritanserin, olanzapine 
and MD 100907 show different selectivity and have been developed for the treatment 
of schizophrenia. It appears that the combination of dopamine D2 and 5-HT2A 
receptor antagonism may best explain the antipsychotic activity of drugs such as  
clozapine, olanzapine, seroquel and others. Moreover, it has been proposed that 
LSD exerts its hallucinogenic effect via interaction with the 5-HT2AR. 
At present, there are no selective agonists for 5-HT2ARs. The agonists for this 
receptor described until now like Me-5-HT, DOB and DOI also recognise other 
receptors of the 5-HT2 receptor subfamily. 
 
1.5 5-HT2AR agonists and antagonists 
 
1.5.1 5-HT2AR agonists 
 
Agonistic activity on 5-HT2AR is essential for the psychopharmacology of serotonergic 
psychedelic or hallucinogenic drugs such as d-lysergic acid diethylamine (LSD), 
psylocibin, 5-MeO-DMT, mescaline and its derivatives (DOB, DOI, DOM). Molecules 
from different structural classes can act as agonists on this receptor, but no cases of 
sufficiently high subtype selectivity have been described up to now. In general, 
hallucinogens can be divided into two classes: 1) tryptamines and 2) 
phenylethylamines.  
 
1.5.1.1 Tryptamines 
 
This class includes two subclasses: 
1. Indolylalkylamines                                                                                                   
5-hydroxytryptamine, the physiological ligand, is a non-selective agonist that 
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binds to all 5-HT receptors. In the 5-HT2 receptor family the affinity for this 
molecule is in the order 5-HT2AR › 5HT2BR › 5HT2CR (Baxter et al., 1995; 
Bonhaus et al., 1995). Structural modifications such as O-methylation or 
methylation in the alkyl chain (Figure 1.9) result in small effects on affinity and 
selectivity (Ismaiel et al., 1990; Nichols et al., 1988).  
 
 
 
 
 
          Figure 1.8:  5-HT2AR (partial) agonists derived from tryptamine 
 
Of particular relevance are 5-HT2AR partial agonistic tryptamine derivatives with 
hallucinogenic activity (Nichols, 2004) such as DMT, 5-Me-O-DMT, bufotenin, a 
compound secreted from the skin of Common Toad (Bufo Bufo) and psylocibin, 
a prodrug of psilocin extracted from a mexican mushroom (Psilocybe mexicana) 
(Hasler et al., 1997; Horita, 1963; Horita and Weber, 1961) (Figure 1.10).  
 
 
 
 
 
 
 
 
 
 
          Figure 1.9: Representative 5-HT2AR partial agonists with hallucinogenic effects  
   
2. Ergolines 
Ergolines, one of the pharmacologically most important groups of indole 
alkaloids isolated from the dried sclerotium of the fungus Claviceps purpurea 
(ergot), are relatively rigid analogs of tryptamine (e.g. lysergic acid diethylamide 
and some closely related compounds, see Figure 1.11). They are well known for 
their strong hallucinogenic effects. The scientific story of hallucinogens began in 
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1943, when Dr. Albert Hofmann, a natural products chemist from Sandoz 
experienced unusual mental effects following work with LSD. All compounds 
have two chiral centers in positions 5 and 8. Only the (5R,8R)-isomers display 
partial agonistic activity and hallucinogenic effects (Isbell et al., 1959; Rothlin, 
1957). These molecules are without any selectivity for the 5-HT2AR. Their 
affinities for 5-HT1A, 5-HT1D, 5-HT2A, 5-HT2C, 5-HT5, 5-HT6, 5-HT7, D2- and α1 
adrenergic receptors are very similar (Aghajanian and Marek, 1999; Glennon, 
1990; Marek and Aghajanian, 1996). 
 
 
 
 
 
 
                             
Figure 1.10: Nonselective 5-HT2AR partial agonists: LSD and derivatives with hallucinogenic 
effect 
1.5.1.2 Phenylalkylamines 
 
Mescaline (3,4,5-trimethoxy-β-phenethylamine) is the main ingredient of peyote 
(Lophophora williamsii), a member of the Cactaceae family representing one of the 
earliest known hallucinogenic plants. This molecule was first identified by Heffter in 
1896 and recognized as the active hallucinatory agent of this plant (Heffter, 1896). 
Following the first chemical synthesis of mescaline in 1919 (Späth, 1919), this 
molecule served as prototypical structure in more than 75 years of structure-activity 
relationships (SAR) studies linking molecular structure to hallucinogenic or psych-
edelic activity (Nichols, 1986). The SAR studies have led to agents with the common 
structure shown in Figure 1.11 and with low nanomolar affinity for 5-HT2A and 5-HT2C 
receptors (Glennon et al., 1992; Heller and Baraban, 1987; Lyon et al., 1988; 
Rasmussen et al., 1986; Sanders-Bush et al., 1988; Seggel et al., 1990). Some of 
which are among the most potent partial agonists with hallucinogenic effects known 
to data (Glennon et al., 1982; Glennon et al., 1980).  
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Figure 1.11: Mescaline and the general structure of new potent 5-HT2AR partial agonists obtained 
from SAR studies 
 
The high affinity of these molecules is due to the two methoxy groups in position 2 
and 5. Introduction of a substituent in position 4, such as a methyl (DOM), an ethyl 
(DOEt) or a halogen function like bromine (DOB) or iodine (DOI) further enhances 5-
HT2AR affinity and partial agonistic activity. Introduction of other lipophilic 4-substitu-
ents such as hexyl (DOHx) and benzyl (DOBz)  also increases affinity, but leads to 5-
HT2AR antagonism (Seggel et al., 1990) (Figure 1.12).  
 
Figure 1.12: Dimethoxyphenylalkylamine derivatives with substituents in position 4: a. molecules with 
5-HT2AR partial agonistic activity, b. molecules with 5-HT2AR antagonistic activity. 
 
All these molecules contain a chiral centre in the alkyl chain. In vitro tests with DOB 
and DOI have clarified which enantiomer is the eutomer and which is the distomer 
(Johnson et al., 1987; Seggel et al., 1990). The HT2AR affinity is two times higher for 
the R enantiomers than for the racemates. Therefore, the eutomers have an R 
configuration. A large number of compounds has been synthesised starting from 
DOB and DOI. This class of molecules and in particular DOB and DOI are also used 
as radioligands ([3H]-DOB, [125I]-DOI) for labelling 5-HT2 receptors.  
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A very interesting class of tricyclic phenylalkylamines showing partial agonistic 
activity on 5-HT2AR is represented by the general structure in Figure 1.13.  
 
 
 
 
 
Figure 1.13: General structure of tricyclic phenylalkylamine 5-HT2AR partial agonists.  
 
In this structure a halogen substituent Y at the phenyl ring plays a key role for the 
affinity. The presence or absence of a alkyl substituent in α position (R) of the alkyl 
chain is of less influence. The tetrahydrobenzofuran ring representing a rigid analog 
of the dimethoxyphenyl moiety is in an optimal orientation for high 5-HT2AR affinity 
(Oh et al., 2001). Figure 1.14 shows some tetrahydrobenzofuran derivatives. 
 
 
 
 
 
 
 
Figure 1.14: Selected tetrahydrobenzofuran derivatives with partial agonistic activity on the 5-HT2AR 
and their Ki values. 
1.5.1.3 Quinazolinediones – a new partial agonistic structure 
 
A relatively new class of agonists identified in SAR studies focused on analogs of the 
5-HT2A receptor antagonist ketanserin is represented by quinazolinedione 
derivatives. EZS-8, quasi the quinazolinedioneethylamine moiety of ketanserin, 
unexpectedly displayed partial 5-HT2AR agonistic activity. Further studies on this new 
chemical class led to the new potent partial agonist RH-34 (Figure 1.15).  
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Figure 1.15: Lead discovery and optimization starting from the reference 5-HT2A  receptor antagonist 
ketanserin. Compound EZS-307 represents the new lead. 
 
Surveying the different classes of arylalkylamines described above (including 
ergolines as cyclisized derivatives), it is possible to define three general requirements 
for optimal partial 5-HT2AR agonistic activity:  
1. An amino nitrogen (protonated at pH 7), separated from the aromatic ring by 
two carbon atoms. 
2. Presence of two electron donors (or acceptors) in the aryl moiety. 
3. A hydrophobic substituent at the aryl moiety increases affinity and activity. 
 
1.5.2 5-HT2AR antagonists  
 
When serotonin interacts with the 5-HT2AR, both peripheral and CNS processes are 
affected. Antagonists of this receptor (Figure 1.8) are potentially useful for the 
treatment of cardiovascular disorders (hypertension, ischemia, platelet aggregation 
and migraine), schizophrenia, anxiety, as well as sleep and nutritional disturbances. 
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Figure 1.16: Structures of selected 5-HT2AR antagonists active in the cardiovascular system and the 
CNS. 
 
Many 5-HT2AR antagonists contain an alkylpiperidine or alkylpiperazine partial 
structure. Ketanserin was discovered in 1981 (Leysen et al., 1981) and has been 
suggested to have therapeutic potential in hypertension as well as in peripheral 
vascular diseases (Brogden and Sorkin, 1990; Vanhoutte et al., 1988) and to protect 
the ischemic myocardium (Grover et al., 1993). Ketanserin is selective for 5-HT2AR 
vs. 5-HT2CR (15-80fold) and 5-HT2BR (500-1000fold) (Jerman et al., 2001) and 
weakly active on 5-HT3R, 5-HT4R and members of the 5-HT1R subfamily. It blocks 5-
HT induced platelet adhesion. The antihypertensive effects of ketanserin are 
probably be due to its high affinity for α1 adrenergic receptors. Ritanserin is a more 
specific 5-HT2AR antagonist with low affinity for α1-adrenergic receptors and, as it 
increases cerebral blood flow, can be used in the treatment of cerebral ischemia 
(Bach et al., 1998). Cyproheptadine, acting also as histamine H1R and calcium 
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channel antagonist, blocks 5-HT activity on smooth muscles via the 5-HT2AR but 
does not effectively lower blood pressure. (Xin et al., 1994). Another potent and 
selective 5-HT2AR antagonist is AT-1015 inhibiting 5-HT2AR-mediated platelet 
aggregation and 5-HT induced vasoconstriction (Kihara et al., 2000). 
5-HT2AR antagonists which cross the blood-brain barrier are antipsychotic and called 
atypical neuroleptics or atypical antipsychotics. In addition to their 5-HT2AR 
antagonistic effect, they block different dopamine receptor subtypes. Most drugs of 
this kind of action belong to the class of tri- or tetracyclics. Clozapine was the first 
member, developed by Sandoz in 1961, and is the reference drug for atypical 
antipsychotics, used principally in treatment-resistant schizophrenia (Wahlbeck et al., 
2000). The therapeutic effects are probably mediated by blocking both dopaminergic 
and serotonergic activity (Naheed and Green, 2001). Loxapine and olanzapine are 
molecules related to clozapine and are also used for the treatment of schizophrenia, 
but with less side effects. Other antipsychotic agents like risperidone and ziprasidone 
are not tricyclics but belong to the alkypiperidine class. They are 5-HT2AR antagonists 
with more or less affinity on dopamine receptors and employed in the treatment of 
schizophrenia and bipolar disorders, respectively. 
Also many ergolines show high affinity for 5-HT2AR and 5-HT2CR. An example is 
methysergide with additional partal agonistic activity on certain 5-HT1 receptor 
subtypes. Methysergide is used for the prophylactic treatment of migraine. Another 
and quite new 5-HT2AR antagonist acting on the cardiovascular system is 
sarpogrelate, not referable to the structural classes described above. This compound 
has been introduced as therapeutic agent for the treatment of ischemic diseases 
associated with thrombosis (Ito and Notsu, 1991).  
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Serotonin (5-hydroxytryptamine, 5-HT) receptors belong, with one exception, to the 
class of G-protein coupled neurotransmitter receptors (GPCR). Minor structural 
modifications of their ligands often result in major changes of the qualitative activity 
profile (Heim et al., 1998; Pertz et al., 2000). E.g., structurally closely related 
molecules may behave as full agonists, partial agonists or pure, "silent" antagonists 
in functional in-vitro assays on isolated organs. The rational base of such 
phenomena is not known up to date. Their investigation can considerably contribute 
to our knowledge about how signal molecules activate receptors at the molecular 
level.  
In the context of SAR studies on chiral und achiral ligands of 5-HT2A receptors (Elz et 
al., 2002; Heim et al., 2002), a structural concept has been derived by which the 
partial agonistic activity of mostly less potent 5-HT2A agonistic primary amines as 
serotonin (5-HT), 3-(2-aminoethyl)quinazoline-2,4-dione, mescaline, and 1-(4-bromo-
2,5-dimethoxyphenyl)-isopropylamine (DOB) was increased by a factor of 50 to 2000 
(Elz et al., 2002; Heim et al., 1998; Pertz et al., 2000). The most interesting 
derivatives are partial agonists (Emax 30-60% in vascular in-vitro assays on rats) and 
up to 400-1400 times more potent than 5-HT. This was obtained by introduction of an 
ortho-methoxybenzyl or -hydroxybenzyl substituent at the amine nitrogen and has 
been successfully confirmed, e. g., in a series of phenethylamines related to 
mescaline. 
The present study was based on a series of 51 arylethylamines from the group of S. 
Elz. All the compounds are 5-HT2AR partial agonists and belong to three different 
structural classes, (1) indoles, (2) methoxybenzenes (including benzodifurans as 
cyclic analogs) and (3) quinazolinediones. The aim of the project was to analyze the 
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quantitative structure-activity relationships (QSAR) and to suggest 5-HT2AR binding 
modes. Following a hierarchical strategy, different methods should be applied which 
all contribute to the investigation of ligand-receptor interactions: fragment regression 
analysis (FRA), receptor modeling, docking studies and 3D QSAR approaches 
(comparative molecular field analysis, CoMFA, and comparative molecular similarity 
index analysis, CoMSIA).  
Initially homology models of the human and rat 5-HT2AR had to be derived from the 
bovine rhodopsin crystal structure (Palczewski et al., 2000). During the last phase of 
the project and after completion of the QSAR study, the crystal structure of the 
human β2-adrenoceptor was released (Cherezov et al., 2007; Rasmussen et al., 
2007; Rosenbaum et al., 2007). With this template, more reliable homology 5-HT2AR 
models have been possible. Therefore all the structure-based methods and analyses 
applied before were to be repeated, also offering the opportunity to compare the 
models and docking results from both approaches. 
Due to the similarity of GPCRs and also of both templates in the structurally 
conserved regions of the seven transmembrane domains, homology modeling was 
expected to yield reliable structural models of human and rat 5-HT2A receptors. 
Conserved intramolecular interactions predicted to be involved in receptor 
stabilization and to play a functional role as well as putative ligand binding sites had 
to be explored considering in-vitro mutagenesis data and SAR of agonists and partial 
agonists. The docking of representative compounds of each structural class was to 
suggest common and/or individual ligand-receptor interactions which must not 
disagree with the fragment regression analysis and with the ligand-binding properties 
of receptor mutants. The docking poses should serve as templates for a common, 
binding-site based alignment of the whole series. Based on this alignment, the 
CoMFA and CoMSIA approaches were to analyze the QSAR in detail, leading to 
interaction fields which may be projected onto the binding site models and, by this, 
may refine the exploration of the SAR and the ligand-receptor interactions. 
Since the series to be analyzed consists of partial agonists assumed to stabilize 
either a specific, partially active state of the receptor or a fully active state to a lesser 
extent than agonists, and since the existing crystal structures represent inactive 
states, more informations about active receptor conformations are needed. Based on 
models of different rhodopsin states (refs. Ishiguro), a homology modeling study on 
corresponding 5-HT2AR states suggested to be specific to agonist and partial agonist 
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binding, respectively, was to be performed. Two  photointermediates in the rhodopsin 
photocascade, metarhodopsin I380, and metarhodopsin II, should serve as templates 
for the partially active and the fully active h5-HT2AR state, respectively. The homology 
models to be derived and docking studies with representative partial agonists and 
agonists should provide informations on specific interhelical and ligand-receptor 
interactions accounting for differences between active and inactive states, for the 
stabilization of the individual conformations and for possible reasons that the 
compounds of the arylethylamine series act as partial agonists. 
In summary, this thesis was aimed to investigate the QSAR of 5-HT2AR partial 
agonists at a structure-based level and to provide reasonable suggestions how the 
compounds interact with the receptor. 
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3.1 GPCR homology models in medicinal chemistry 
 
Direct and detailed insights into GPCR structures were limited for a long time. Today, 
however, the crystal structures of two GPCRs are available:  
1. The 2.8 Å resolution structure of bovine rhodopsin published in 2000 
(Palczewski et al., 2000), and four additional structures which can be retrieved 
from the Brookhaven Protein Data Bank (PDB) (Bernstein et al., 1977) by the 
identity codes 1F88 (Palczewski et al., 2000), 1HZX (Teller et al., 2001), 1L9H 
(Okada et al., 2002), 1GZM (Li et al., 2004), and 1U19 (Okada et al., 2004).  
2. Crystal structures of the first GPCR, the human β2 adrenoceptor, resolved in 
2007 with different resolution (3.7 Å, 3.4 Å and the best 2.4 Å) The PDB identity 
codes are 2R4R, 2R4S (Rasmussen et al., 2007) and 2RH1 (Cherezov et al., 
2007; Rasmussen et al., 2007; Rosenbaum et al., 2007). 
The crystal structure of bovine rhodopsin has been used for 7 years as template for 
modeling of GPCRs. With the acquisition of the β2 adrenoceptor the world of GPCR 
modeling is going to change in particular with respect to more reliable approximations 
of the ligand binding sites of biogenic amine receptors. 
In general the modeling of a GPCR based on a homologous template is named 
homology modeling. The lack of detailed information about GPCR structures led to 
the quest for three dimensional (3D) structural models. Knowledge-based approa-
ches were developed to predict the 3D structure of proteins based on experimental 
data of the 3D structure of homologous reference proteins. Using these approaches it 
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is possible to provide insight into molecular mechanisms of GPCR function and 
activity (Kristiansen, 2004). The steps used to predict the specific role of amino acids 
for the binding of ligands and the regulation of GPCR activity are shown in Figure 
3.1. The prediction can subsequently be used as guideline for the construction and 
characterization of point mutations, studies of ligand-receptor interaction, and the 
design of new leads by application of flexible docking and virtual screening methods 
(Bissantz et al., 2003). 
 
Figure 3.1: Flowchart of steps in homology modeling and possible application of homology models in 
computational (in silico) medicinal chemistry and in vitro pharmacology. 
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3.2 Protein Database 
 
The first step in homology modeling is to obtain the amino acids sequence of the 
protein from a protein database. These and additional informations from the 
database website are used with different aims such as the prediction of the 
secondary and tertiary structure of the protein and the identification of functional 
properties (Figure 3.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Flowchart for the prediction of a protein tertiary structure 
 
Of particular relevance are the databases of three dimensional structures such as the 
Cambridge Structure Database, CSD (Allen, 2002) and the Protein Data Bank, PDB 
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(Berman et al., 2000). The first is an archive of structures, fragments and molecules 
with low molecular weight used for virtual screening or de novo design with the aim to 
identify new molecules with pharmacological activity. The second, the PDB database 
contains structures of macromolecules (proteins and nucleic acids) obtained experi-
mentally (NMR or X-ray) or by homology modeling. 
 
3.3 Sequence alignment 
 
An important step in homology modeling is to align the amino acid sequence of the 
target protein with the sequence(s) of the template protein(s). Correspondences 
(identities and conserving mutations) of amino acids are the basis for transferring the 
coordinates from the template(s) to the target. 
Usually automatic sequence alignment tools are used to search for optimal similarity 
of the sequences. Sequence comparisons are carried out either pairwisely (e.g. 
ALIGN (Devereux et al., 1984)) or as multisequence alignment  (e.g. CLUSTAL W 
(Thompson et al., 1994)). Most sequence alignment algorithms try to retrace the 
evolutionary conversion of one sequence into another. For this operation homology 
matrices are used that specify the weight for aligning a particular type of amino acid 
substitution according to physical and chemical properties and/or statistical  and 
evolutionary probabilities. In cases of different sequence lengths and variations in the 
locations of conserved regions, gaps are introduced into the alignment. To minimize 
the number of gaps, a gap penalty function is used. 
 
3.4 3D structure generation 
 
The 3D structure of the target protein is generated in a stepwise approach. The first 
step is the construction of structurally conserved regions (SCRs). This can be 
obtained by two different methods. The first approach is often sufficient if only one 
template is available. It starts from a good sequence alignment and proceeds with 
manual mutation of the template protein into the target sequence in conserved 
streches (stretches without gaps and deletions). For GPCR modeling, the SCRs are 
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the TMs and short loop regions. Nearly the same results can be obtained using a 
second class of multiple-template methods, namely Composer (originally derived by 
the group of Tom Blundell before 1990, (Sali et al., 1990)) or Fugue/Orchestrar (Shi 
et al., 2001) which is available online, too. Fugue permits to recognize distant 
homologs by sequence-structure comparison and is based on three key features: (1) 
Improved environment-specific substitution tables. Substitutions of an amino acid are 
constrained by its local structural environment, which can be defined in terms of 
secondary structure, solvent accessibility, and hydrogen bonding state. (2) Automatic 
selection of an alignment algorithm with detailed structure-dependent gap penalties 
(global-local algorithm when sequence-structure pairs greatly differ in lengths and 
global algorithm in other cases). The gap penalty at each position of the structure is 
determined according to its solvent accessibility, its position relative to the secondary 
structure elements (SSEs) and the conservation of the SSEs. (3) Combined 
information from both multiple sequences and multiple structures. Fugue is designed 
to align multiple sequences against multiple structures to enrich the 
conservation/variation information. Based on such optimal sequence alignments, 
Composer or Orchestrar determine the SCRs and an average SCR-Cα framework 
structure of the templates by an iterative approach, improving both the multiple 
alignment and the subsequent SCR framework by pair-wise Needleman and Wunsch 
dynamic programming procedures with a similarity matrix constructed from inter-Cα 
distances. The backbone of each SCR of the target is then built by fitting the 
corresponding SCR from one of the known homologs (namely that with the highest 
block sequence identity) to the appropriate region of the framework. The least-
squares fits are inversely weighted by the variation of the residue positions across 
the known structures. This approach provides a sufficient degree of diversity on 
constructing the SCRs of the target and avoids an arbitrary focus on one of the 
templates. 
The second step in homology modeling is the construction of structurally variable 
regions (SVRs) including regions in the amino acid sequence that contain gaps and 
deletions. In GPCRs these regions usually comprise the extracellular and intracellular 
loops (except I1, E1 and I2), the N-terminus and the C-terminus that show a low 
sequence homology and different lengths. A convenient method to build such regions 
is to perform loop searches for appropriate peptide segments in a 3D structure 
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database (usually a binary version of the PDB). The selected segments are chosen 
on the basis of their superposition with the anchor regions (the terminal amino acids 
of the loop to be constructed) and their fit into the spatial environment of the target 
model. Another possibility is to generate loops using a de novo strategy. 
After the generation of the complete receptor backbone the next step is the addition 
of the side chains. Normally this step starts from the assumption that identical and 
conserved residues in homologous proteins adopt similar side chain conformations. 
In case of non conserved amino acids rotamer libraries can help in the selection of 
reasonable geometries. Rotamer libraries such as the Lovell library (Lovell et al., 
2000) implemented in Sybyl 7.3 (Tripos, St. Luis, MO) contain a collection of statisti-
cally favoured side chain conformations from which the most frequent one without 
clashes with other residues can be selected. 
Modeling software suites like Sybyl contain structure preparation tools to complete 
the models. Such tools are to add hydrogens, to provide the atoms with net charges, 
and to remove bad contacts from individual side chains. The last step in the 3D 
model generation is the energy minimization. For biopolymers, Kollman et al. (Weiner 
et al., 1984) originally derived a force field with energy terms, parameters and 
functions especially suited for proteins and nucleic acids. The most recent versions of 
this force field are now available as Amber_FF99 and Amber_FF02 (Cieplak et al., 
2001; Wang et al., 2000) in all advanced modeling packages. 
 
3.5 Model validation 
 
After GPCR homology models have been generated and structurally optimized, 
validation of the resulting models is an essential task to guarantee applicability of the 
models for the particular purposes of the project. The most important parameters 
evaluated are described in Figure 3.3. 
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Figure 3.3: Overview of parameters for the validation of GPCR homology models 
 
For an evaluation of the stereochemical quality of a structure model, programs such 
as PROCHECK (Laskowski et al., 1993) and WHATCHECK (Hooft et al., 1996) have 
been developed. An overall estimation of structural differences between the 
backbone structures of the target and the template can be obtained by calculating the 
root mean square deviation (RMSD) of all backbone or Cα atoms. Additionally, the 
total number of intramolecular H-bonds, the radius of gyration, and the solvent-
accessible surface area give valuable measures of the protein global folding. Finally, 
distinct interactions between adjacent residues that may play a functional role in 
GPCR function and/or structural arrangement of the TM domains have to be 
checked. 
 
3.6  3D Quantitative Structure-Activity Relationships (3D QSAR) 
 
A major goal in chemical research is to predict the potency or receptor affinity of new 
molecules, using relationships derived from analysis of the properties of previously 
tested molecules. Quantitative Structure-Activity Relationships (QSAR) (Kubinyi, 
1993, 1995) correlate measurable or calculable physical, chemical or topological 
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descriptors with biological activity by (mostly linear) mathematical models. A QSAR 
study can help to decide which features of a molecule give rise to its potency and 
help to predict compounds with desired properties. A large number of descriptors 
have been used in QSAR equations, designed to represent hydrophobic, electronic 
or steric properties of the molecule. An important point for their choice is that they 
should be uncorrelated with each other to obtain a reliable QSAR equation.  
3D-QSAR methods are to correlate biological activities with molecular field variables, 
representing the geometry of the molecules and their spatial interaction potential. 
Several 3D-QSAR approaches have been described: methods based on molecular 
shapes, the “distance geometry” method, DYLLOMMS, a prototype version of 
CoMFA, as well as CoMFA and CoMSiA. 
Comparative Molecular Field Analysis (CoMFA) (Cramer et al., 1988) is an approach 
to structure-activity correlation based on two observations: (1) at the molecular level, 
the interactions which produce a biological effect are usually noncovalent; and (2) 
molecular mechanics force fields, most of which treat noncovalent interactions only 
as steric and electrostatic forces, can sufficiently account for a great variety of 
observed molecular properties. Thus it seems reasonable that a suitable sampling of 
steric and electrostatic fields surrounding a set of ligand (drug) molecules might 
provide all the information necessary for understanding their biological actions. In 
general the CoMFA approach correlates the interaction potential of ligands, 
calculated from the interaction energy with probe atoms at regular spaced grid points 
surrounding the aligned structures, with the biological activity. 
Comparative Molecular Similarity Index Analysis (CoMSIA) (Klebe et al., 1994) is 
based on the same assumption as CoMFA: changes in biological activities or binding 
affinities of ligands are related to changes in molecular properties, represented by 
fields. CoMSIA is an extension of the CoMFA approach. In addition to the 
electrostatic and steric fields, hydrophobic, H-bond donor and H-bond acceptor fields 
are considered. Moreover, the CoMSIA field variables are based on "soft" Gaussian 
functions showing a more continuous distribution of the interaction potentials around 
the molecules, compared to the mostly large gradients of the CoMFA potentials in 
regions close to or within the van der Waals surfaces.  
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The 3D-QSAR models are solved by the partial least squares (PLS) approach (Wold 
et al., 1984) which, in general, decomposites the huge number of more or less 
intercorrelated field variables into only a few orthogonal principal components (PCs) 
being in turn maximally correlated with the biological activity. The justification of the 
models and the number of PCs describing activity without noise are evaluated by the 
error of predictions from leave-n out runs (activity of omitted compounds predicted by 
the model of all other compounds). Finally, a model including all molecules is 
calculated, and the components are transformed into regression coefficients 
describing the direction and the strength of the influence of each field variable on 
activity. 
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4 Docking of representative partial agonists at 5-HT2A 
receptor models based on rhodopsin 
 
 
Chapter 4 
Docking of representative partial 
agonists at 5-HT2A receptor models 
based on rhodopsin  
 
 
4.1 Introduction 
 
5-HT2A receptors (5-HT2AR) (Peroutka, 1990) belong to the G-protein coupled 
receptor superfamily (GPCR) and mediate the effects of the endogenous 
neurotransmitter serotonin (5-hydroxytryptamine, 5-HT) As described in Chapter 1, 5-
HT2AR mediated signal transduction affects a large number of key physiological 
processes including vascular and nonvascular smooth muscle contraction, platelet 
aggregation, perception and affective behaviour (Roth et al., 1998; Zifa and Fillion, 
1992). Additionally, 5-HT2A receptors represent a major site of action of hallucinogens 
like ergolines (e.g., lysergic acid diethylamine), phenylalkylamines (e.g., 1-(4-iodo-
2,5-dimethoxyphenyl)-isopropyl amine, DOI) and substituted tryptamines (e.g., N,N-
dimethyltryptamine, DMT). In most assays, these compounds act as partial 5-HT2AR 
agonists. The affinity of the endogenous agonist 5-HT is relatively low (pKD ca. 6). 
Dimethoxyphenylalkylamines like mescaline and 1-(4-bromo-2,5-dimethoxyphenyl)-
isopropylamine (DOB) are more affine and potent. By introduction of larger 
substituents at the amine nitrogen it is possible to gain partial agonists that are up to 
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400-1400 times more active than 5-HT due to higher affinity. This "affinity-conferring" 
principle may be applied to other structural classes as indoles and quinazolinediones. 
To obtain still more potent 5-HT2AR agonists and to investigate structure-activity 
relationships (SAR), a series of more than 60 compounds was synthesized and 
tested for 5-HT2AR agonistic potency (pEC50) and intrinsic activity (Emax) on rat 
arteries (Elz et al., 2002; Heim et al., 1998; Heim et al., 2002; Pertz et al., 2000; 
Ratzeburg et al., 2003). The series comprises diverse primary and secondary 
arylethylamines belonging to different structural classes (mainly indoles, 
methoxybenzenes and quinazolinediones), and shows a high variability of pEC50 
from 4 to 10 and of Emax (intrinsic activity compared to 5-HT) from 15 to 70%. The 
QSAR of the compounds were analyzed following a hierarchical strategy with 
successive application of different methods: fragment regression analysis (FRA), 
receptor modeling, docking studies, and 3D-QSAR approaches. Generally, all these 
methods contribute to the investigation of ligand-receptor interactions.  
During the first 2 ½ years of the present PhD project, homology modeling had to be 
based on bovine rhodopsin, the only available GPCR structure at that time (Okada et 
al., 2002; Okada et al., 2004; Palczewski et al., 2000; Teller et al., 2001).This chapter 
is to analyze the docking of key compounds at 5-HT2AR models derived from this 
template. In the meantime, crystal structures of the human β2-adrenoceptor have 
been released (Cherezov et al., 2007; Rasmussen et al., 2007) that are better suited 
for the generation of homology models of GPCRs. Therefore, it was necessary to 
repeat all the steps except FRA which does not depend on the template. To avoid 
battologies, the QSAR analysis of the series, derived from using the recent 5-HT2AR 
models, will be presented and discussed as a whole (see Chapter 5). 
In principle it should be possible to explore the putative 5-HT2AR binding modes of 
the ligands in considering one ligand of each class. Homology models of the rat (r5-
HT2AR) and the human (h5-HT2AR) 5-HT2A receptor based on the crystal structure of 
bovine rhodopsin (Filipek et al., 2003a; Filipek et al., 2003b) together with results 
from in-vitro mutagenesis studies predict the location, topology and the amino acids 
of the agonist binding site. The docking of a representative compound of each 
structural class into this site suggests common and/or individual ligand-receptor 
interactions, which must not disagree with the ligand binding properties of the 
receptor mutants. 
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4.2  Material and Methods 
 
4.2.1 Model construction  
 
Three-dimensional models of the human (h5-HT2AR) and the rat 5HT2A receptor (r5-
HT2AR) were generated by homology modeling. The amino acid sequences were 
retrieved from the Swissprot database. The homology between both receptor species 
is very high. The most different regions are the N- and C-terminal segments. The 
identity of the transmembrane domains amounts to 97%, only three amino acids in 
TM1, TM3 and TM5 are different. The crystal structure of bovine rhodopsin at 2.8 Å 
resolution (Palczewski et al., 2000) strongly supports the homology modeling of 
GPCRs (Filipek et al., 2003a; Filipek et al., 2003b) and permits to construct a 
backbone model of the almost full length of the studied protein by a Fugue/Orches-
trar approach (Shi et al., 2001). The full sequence of the h5-HT2AR was submitted 
using bovine rhodopsin as template. The starting structure was chosen from several 
models on the basis of: 
a) the sequence alignment with bovine rhodopsin considering the TM domains 
(with the dopamine D2 receptor – rhodopsin alignment as reference 
(Ballesteros et al.)) and the intra- and extracellular loops with corresponding 
lengths; 
b) the known packing of the seven transmembrane helices; 
c) the disulfide bridge between Cys (148) and Cys (272); 
d) the length of gaps. 
Orchestrar was not able to predict the 3D structure of some domains of the receptor 
(E2 loop, I3 loop and C-terminus). The gaps in E2 and I3 were filled by the 
Biopolymer loop search facility (Sybyl 7.3 (Luthy et al., 1992b)) with appropriate 
peptide chains from a binary protein database based on PDB structures (Palczewski 
et al., 2000). The final insertions resulted from: 
a) the source of the fragment;  
b) the sequence homology score;  
c) the fit of the chain into the model.  
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The C-terminus was truncated after the H8 helix. Side chains and hydrogens were 
added using the Biopolymer package of Sybyl 7.3. The model was initially relaxed 
with steepest descent minimization using the Amber FF99 force field, Amber FF99 
charges and a distant dependent dielectric constant of 4, until the RMS gradient 
approaches 0.5 kcal mole-1 Å-1 . During the first 100 cycles, the backbone was fixed. 
This initial optimization was followed by a Powell minimization (end RMS gradient 
0.01 kcal mole-1 Å-1). To verify the integrity of the structure, as last step the optimized 
receptor model was submitted to 3D-Verify and Procheck (Luthy et al., 1992a). 
Starting from the initial h5-HT2AR model some amino acids were mutated to obtain 
the corresponding model of the rat receptor which was energy optimized and verified 
as described for the h5-HT2AR model.  
 
4.2.2 Ligand selection, structure generation and docking 
 
The selection of one representative compound from each structural class – (1) 
indoles, (2) methoxybenzenes, (3) quinazolinediones – of the arylethylamine series 
of 5-HT2AR partial agonists was based on high potency and reproduction of all 
favourable ligand-receptor interactions. Among the substituents at the amino nitrogen 
which were similarly varied in each subseries (see Table 5.1) a 2-methoxybenzyl 
group is optimal. Therefore each class was represented by a derivative containing 
this substituent. Figure 4.1 depicts the selected compounds, namely, 201 (indole), 
231 (methoxybenzene) and 169 (quinazolinedione class) (numbering according to 
Table 5.1). 
  
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Representative structure used in the docking studies 
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The structures were constructed using Sybyl 7.3. All molecules were assumed to be 
protonated under physiological conditions. AmberFF99 atom types and Gasteiger-
Hückel charges were assigned to the ligands. Based on the assumption that the 
ligands share a common binding site at the receptor, a structure-based alignment 
was to be achieved. I.e., the docking modes (bioactive conformations) must rely on 
informations about the location of putative binding site residues. Site-directed 
mutagenesis studies have indicated that the highly conserved Asp1553.32 (Sealfon et 
al., 1995; Wang et al., 1993), the serines Ser1593.36, Ser2395.43, Ser2425.46 (Ala242 in 
r5-HT2AR), (Johnson et al., 1994) and the phenylalanines Phe2435.47, Phe2445.48, 
Phe3406.52 (Choudhary et al., 1993; Choudhary et al., 1995) are important for binding 
and efficacy of agonists and partial agonists at 5-HT2A receptors. These results 
restrict the agonist binding site to a well defined region between TMs 3 to 6 and 
suggest Asp1553.32 as counterpart of the protonated amine, Ser1593.36, Ser2395.43 
and Ser2425.46 as hydrogen donors or acceptors, and the phenylalanines in TM 5 and 
6 as hydrophobic pocket and anchor for the aryl moiety of the ligands.  
The ligands were manually docked into the putative binding site, also considering the 
QSAR obtained from fragment regression analysis (see Chapter 5). During docking, 
the conformations of the ligands were varied in order to get maximal overlap of the 
scaffolds and shared interactions with the essential amino acids described above. 
The fit of the "affinity conferring" N-benzyl groups was based on the examination of 
proximate amino acids and on low-energy conformations. The complexes were 
optimized by a stepwise approach: (1) 50 cycles AmberFF99 force field with fixed 
ligands (distant dependent dielectric constant 4, steepest descent method), (2) 
subset minimization of the ligand and a receptor region 6 Å around using the 
combined protein-ligand force field MMFF64 (distant dependent dielectric constant 1, 
Powell method) up to an RMS gradient of 0.05 kcal mole-1 Å-1), (3) AmberFF99 force 
field with fixed ligands (distant dependent dielectric constant 4, Powell method, final 
RMS gradient 0.01 kcal mole-1 Å-1). Range constraints were occasionally applied 
between Asp1553.32 and the protonated nitrogen of the ligands, additionally for cpd. 
231 between Ser1593.36 and the 2-OCH3 group and between Ser2395.43 and the 5-
OCH3 substituent. 
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4.3 Results and Discussion 
 
4.3.1 5-HT2A receptor models 
 
In the h5-HT2AR and the r5-HT2AR models, the packing of the seven transmembrane 
regions and the typical interactions stabilizing the inactive state (dark state) of bovine 
rhodopsin are conserved (Figure 4.2).  
 
 
Figure 4.2: Selected interactions responsible for the inactive state of 5-HT2A receptors. A) Ionic 
interactions between two amino acids belonging to the DRY motif (Asp 1723.49 and Arg 1733.50) and 
Glu 3186.30. B) Polar interactions between TM2 (Asp1202.50) and TM7 (Asn3764.49 and Ser 3737.46). 
 
The homology model suggests that the inactive state is stabilized by two salt bridges 
of Arg1733.50 with the neighbouring Asp1723.49 and with Glu3186.30, respectively. The 
three amino acids are highly conserved in the GPCR superfamily, Arg1733.50 and 
Asp1723.49 belong to the DRY consensus motif. Other polar interactions suggested to 
stabilize the inactive state involve the transmembrane domains TM1 (Asn721.50), TM2 
(Asp1202.50) and TM7 (Ser3737.46, Asn3767.49). All these interactions break during 
receptor activation. The second extracellular loop (E2) is only constrained by the 
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disulfide bridge between Cys1483.25 and Cys227E2.15. This implies that E2 is partially 
inserted into the transmembrane part of the receptor. However, the cap derived from 
rhodopsin is rather typical for this template due to the covalently bound retinal and is 
therefore not reliable in the case of biogenic amine GPCRs. In the model, the course 
of E2 is stabilized by a network of intraloop hydrogen bonds. E.g., the backbone of 
Gln216E2.4 is linked with the side chain of Asp2315.35 and with the backbone of 
Asp218E2.6 and Leu229E2.17, and the side chain of Glu224E2.12 with the backbone of 
Lys223E2.11 (Table 4.1). 
 
           Table 4.1: Conserved intramolecular interaction responsible for the inactive state 
Domain Residues Min. distance (Å)* 
  h5HT2A r5HT2A 
TM3 Arg1733.50 - Asp1723.49 2.11 2.63 
TM3-TM6 Arg1733.50 - Glu3186.30 1.95 2.01 
TM7-TM2 Asn3767.49 - Asp1202.50 2.04 2.38 
TM7 Asn3767.49 - Ser3737.46 3.65 4.86 
E2-TM5 Glu216E2.4 - Asp2315.35 2.05 2.17 
E2 Glu216E2.4 - Asp218E2.6 2.26 2.75 
E2 Glu216E2.4 - Leu229E2.17 1.98 2.04 
E2 Glu224E2.12 - Lys223E2.11 2.03 2.01 
             *Distance between the nearest heavy atoms of interacting residues 
 
4.3.2 Docking of representative partial agonists  
 
As representative 5-HT2AR partial agonists of the arylethylamine series (Elz et al., 
2002; Heim et al., 1998; Heim et al., 2002; Pertz et al., 2000; Ratzeburg et al., 2003), 
the compounds 201 (indole), 231 (methoxybenzene) and 169 (quinazolinedione 
class) were selected (see Figure 4.1). The contributions of these aryl fragments to 
the pEC50 values differ by only ca. 0.8 orders of magnitude (ranging from 0.95 for 
quinazolinedione to 1.75 for 2,5-dimethoxyphenyl, see results of FRA, Chapter 5). 
Furthermore, the effects of a 5-methoxy group at the aryl moiety and of a benzyl 
group as RN are similar in each structural class. Therefore an overlapping binding 
mode of the different partial agonists is likely which can be derived from the docking 
of the three ligands into the r5-HT2AR model.  
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Figure 4.3: Binding conformation and 
alignment of compounds 169 (orange), 201 
(green), and 231 (purple). 
 
 
 
 
 
Figure 4.4 shows the complexes of r5-HT2AR with the representative compounds 
169, 201, and 231, respectively, after energy optimization. The alignment of the 
resulting binding conformations is demonstrated in Figure 4.3. 
The binding of the arylethylamine moieties depends on three sites, (1) Asp1553.32 
forming a salt bridge with the protonated amine, (2) a hydrophobic pocket consisting 
of Phe2435.47, Phe2445.48 and Phe3406.52, and (3) serine and threonine residues 
(Ser1593.36, Thr1603.37, Ser2395.43) as possible hydrogen bond acceptors or donors.  
The close and rather flat alignment of the aryl moieties covering TMs 5 and 6 is 
enforced by the "phenylalanine pocket". The binding of many agonists, including 5-
HT, 5-methoxytryptamine, DOB and DOI, is strongly reduced on a Phe340Leu 
mutant (Choudhary et al., 1993; Roth et al., 1997). Phe243Ala mutation increases, 
Phe244Ala mutation decreases DOI affinity (Shapiro et al., 2000). In Figure 4.4, this 
finding is reflected by a projection of the 4-Br substituent of the dimethoxyphenyl 
compound 231 onto Phe2435.47 and Phe2445.48. The resulting hydrophobic inter-
actions may be conserved in the case of an Ala243 mutation. Interestingly, both 
alanine mutants reduce the affinity of the quinazolinedione ketanserin (5-HT2AR 
antagonist) (Shapiro et al., 2000), indicating that the phenyl moiety of cpd. 169 also 
approaches the phenylalanines 243 and 244. Both seem to be important also in the 
active state of the 5-HT2AR, since the alanine mutations strongly reduce the intrinsic 
activity of indole and quinazolinedione agonists. 
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Figure 4.4: View of the r5-HT2A receptor model in complex with cpd. 169 (A.), cpd. 201 (B.) and cpd. 
231 (C.). The putative agonist binding site (C atoms of amino acids in cyan) and the three α helices 
(TM3 in green, TM5 in orange and TM6 in yellow) are shown. The dotted lines in white represent the 
interaction between the ligand and the residues.  
 
For 5-HT, two alternative binding modes have been published. Whereas Shapiro et 
al. (Shapiro et al., 2000) suggested a H bond of the indole NH with Ser2395.43, 
Johnson et al. (Johnson et al., 1994) postulated an interaction of this serine with the 
5-OH group. The latter mode is more probable since a Ser239Ala mutant reduces the 
affinity of 5-HT 10-fold whereas the binding of tryptamine, 5-methoxytryptamine, 
ketanserin and DOI is less affected. Possibly an H bond of the 5-OMe groups in 5-
methoxytryptamine and DOI is replaced by a hydrophobic or dispersion interaction 
with the alanine residue in the mutant. The FRA results (see Chapter 5) indicate an 
alignment of the 5-OMe substituents of the indole and dimethoxyphenyl derivatives 
which is optimally achieved in close proximity to Ser2395.43. 
An interaction of the indole NH with Ser2425.46 was inferred by Johnson et al. 
(Johnson et al., 1994) from the finding that 5-HT and tryptamine are more affine at 
the human than at the rat 5-HT2AR (Ala2425.46). The question is whether Ser1593.36 
and/or Thr1603.37 may compensate for this interaction in the case of the rat receptor, 
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possibly also as H donor(s) for the indole nitrogen. From results on Ser159Ala 
mutants, Almaula et al. (Almaula et al., 1996) suggested a charge-assisted H bond of 
the hydroxy oxygen with the protonated amino group of 5-HT. As shown in Fig. 4.4, 
on the other hand, Ser1593.36 may be in a position to act as donor in additional H 
bonds with a quinazolinedione oxygen and with the 2-OMe group of the 
dimethoxyphenyl compounds, respectively. In the r5-HT2AR model, the indole NH 
function should rather interact with the side chain of Thr1603.37. 
In conclusion, the models predict bidentate polar interactions of the aryl moieties in 
the case of 5-OH and 5-MeO substituted indoles and 2,5-dimethoxyphenethyl 
compounds, whereas quinazolinediones can form only one H bond in the case of the 
r5-HT2A receptor due to the Ser242Ala mutation. This may contribute to the lower 
activity of the latter.  
The docking pose of the benzyl group at the amino nitrogen was derived from the 
finding that a Phe339Leu mutation does not affect the binding of primary amines like 
5-HT and DOI, whereas secondary amines like ketanserin show reduced affinity 
(Choudhary et al., 1993). In Fig. 4.4, the phenyl moiety of RN aligns with Phe3396.51. 
Since an oxygen in ortho position of the phenyl group (2-OH, 2-OMe) further 
enhances activity, an additional interaction with a hydrogen donor may be suggested. 
In the rhodopsin-based models, the most probable candidate for this interaction is the 
amide group of Asn3436.55.  
 
4.4 Conclusion 
 
In this study, the bioactive conformations and the binding modes of three different 
structural classes of 5-HT2AR partial agonistic arylethylamines – (1) indoles, (2) 
methoxybenzenes, (3) quinazolinediones – were derived. Rat and human 5-HT2AR  
models were generated using the X-ray structure of bovine rhodopsin as template. 
Results from in vitro mutagenesis experiments contributed to the identification of 
important binding site amino acids. Three compounds representing the structural 
classes could be docked at this site in a consistent mode, resulting in a structure-
based alignment which may serve as starting point for 3D QSAR analysis. The 
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question is whether new 5-HT2AR models based on the recent crystal structures of 
the human β2 adrenoceptor will confirm the binding models derived so far.  
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5 5-HT2A receptor partial agonists: QSAR and interactions 
with the binding site 
 
 
Chapter 5 
5-HT2A receptor partial agonists: QSAR 
and interactions with the binding site  
 
 
5.1 Introduction 
 
5-HT2A receptors represent a major site of action of hallucinogens like ergolines (e.g., 
lysergic acid diethylamine), phenylisopropylamines (e.g., 1-(4-iodo-2,5-dimethoxy-
phenyl)-isopropylamine, DOI) and substituted tryptamines (e.g., N,N-dimethyltrypt-
amine, DMT). In most assays, these compounds act as partial 5-HT2AR agonists. The 
affinity of the endogenous agonist, 5-HT, is relatively low (pKi ca. 6). Dimethoxy-
phenylalkylamines like mescaline and 1-(4-bromo-2,5-dimethoxyphenyl)-isopropyl-
amine (DOB) are more affine and potent 5HT2AR agonists. By introduction of larger 
substituents at the amine nitrogen it is possible to gain partial agonists that are up to 
400-1400 times more active than 5-HT due to higher affinity. This "affinity-conferring" 
principle may be applied to other structural classes as indoles and quinazolinediones. 
Following this strategy and with the intention to obtain still more potent 5-HT2AR 
agonists and to investigate structure-activity relationships (SAR), a series of more 
than 60 compounds was synthesized and tested for 5-HT2AR agonistic potency 
(pEC50) and intrinsic activity (Emax) on rat arteries (Elz et al., 2002; Heim et al., 1998; 
Heim et al., 2002; Pertz et al., 2000; Ratzeburg et al., 2003). The series comprises 
diverse primary and secondary arylethylamines belonging to different structural 
classes (mainly indoles, methoxybenzenes and quinazolinediones), and shows high 
variability of pEC50 from 4 to 10 and of Emax from 15 to 70%. To analyse the 
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quantitative structure-activity relationship (QSAR) and to explore the putative 5-
HT2AR binding modes, a hierarchical approach combining different methods was 
applied: (1) fragment regression analysis (FRA), (2) receptor modeling, (3) docking 
studies based on mutagenesis data and FRA results, and (4) 3D QSAR methods – 
comparative molecular field analysis, CoMFA (Cramer et al., 1988b) and comparative 
molecular similarity index analysis, CoMSIA (Klebe et al., 1994). 
Generally, all these methods contribute to the investigation of ligand-receptor 
interactions. FRA provides information about the substructures and substituents 
which strongly affect affinity and potency and, by this, about the nature of effects 
which may play a role in a certain position. Homology models of the rat (r5-HT2AR) 
and the human (h5-HT2AR) 5-HT2AR based on the crystal structure of the β2 
adrenoceptor together with results from in-vitro mutagenesis studies predict the 
location, topology and the amino acids of the agonist binding site. The docking of 
representative compounds of each structural class (indoles, methoxybenzenes and 
quinazolinediones) into this site generates common and/or individual ligand-receptor 
interactions, which must not disagree with the SAR from FRA and with the ligand-
binding properties of the receptor mutants, and provides the templates for a common, 
binding-site based alignment of the whole series. Finally, CoMFA and CoMSIA 
approaches are to analyze the QSAR in detail, leading to interaction fields which may 
be projected onto the binding site model and, by this, refine the exploration of the 
SAR and the ligand-receptor interactions.    
 
5.2 The β2 adrenoceptor, a new template for GPCR homology 
modeling 
 
5.2.1 Crystal structures of the β2 adrenoceptor 
 
For many years, rhodopsin has been the only GPCR with crystallographic information 
available (Okada et al., 2002; Okada et al., 2004; Palczewski et al., 2000; Schertler 
et al., 1993; Teller et al., 2001), providing essential and reliable suggestions about 
the structure and the mechanism of activation of other GPCRs (Hubbell et al., 2003; 
Sakmar et al., 2002). Conclusions relied on mutagenesis experiments combined with 
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sequence comparison and homology modeling. The approach is based on the 
general assumption that evolutionary related proteins, i.e. homologous proteins, 
conserve their 3D structure rather than their amino acid sequence, enabling to derive 
protein models even from significantly distant templates (Costanzi et al., 2006). 
However, the use of rhodopsin as template for GPCR modeling is limited due to 
covalent ligand binding and light-mediated activation, both in contrast to other 
GPCRs (non-covalent binding, ligand-mediated activation). Thus, structurally and 
functionally more similar templates are needed to obtain authentic GPCR models 
which provide further insight into ligand binding and activation mechanisms. 
The recently published crystal structures of the human β2 adrenoceptor (hβ2AR) 
(Cherezov et al., 2007; Rasmussen et al., 2007; Rosenbaum et al., 2007) and of the 
turkey β1 adrenoceptor (tβ1AR, released 1 month before finishing this thesis) (Warne 
et al., 2008) now affords to analyze in particular biogenic amine GPCRs by homology 
modeling without the above limitations. 
A major problem for the crystallization of GPCRs is their low concentration in 
membranes. Other problems arise from the solubilisation by detergents prior to the 
purification of membrane proteins, leading to desintegration of the stabilizing 
membrane lipids. Moreover, the structural flexibility required for the signaling function 
of GPCRs produces conformational heterogeneity that hinders formation of well-
ordered crystals. 
To overcome these problems, the β2AR was modified by: 
- truncation of the C-terminal tail 
- mutation of a site for N-linked glycosylation 
- either replacing residues 231 to 262 of the third intracellular loop (I3) by T4 
lysozyme (T4L), a soluble, easily crystallisable globular protein (Cherezov et 
al., 2007; Rosenbaum et al., 2007) or forming a complex with a Fab5 antibody 
fragment which interacts with an epitope in I3 (Rasmussen et al., 2007) 
(Figure 5.1). 
- binding of a high-affinity inverse agonist, carazolol, to stabilize the structure  
The modification of I3 was a key step for the crystallization, and only the first 
approach (lysozyme insertion) yielded a high resolution structure (2.4Å vs. 3.4-3.7Å 
using Fab5), 
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Figure 5.1: Modifications of the β2 adrenoceptor. The left structure is in complex with a Fab5 fragment 
(two subunits represented in yellow and orange, respectively), and the right structure is an engineered 
β2-AR-T4L fusion protein (T4L violet). The resolution of the two structures is 3.4Å and 2.4Å 
respectively.  
 
5.2.2 Comparison of β2AR and rhodopsin crystal structures 
 
The β2AR consists of seven TM helices connected by intra- and extracellular loops 
(see Figure 5.1). The receptor fold is very similar to that of rhodopsin in its inactive 
state. The overall root-mean-square deviation (rmsd) between the Cα atoms of the 
two structures is 2.3Å. For the TM helices, the rmsd amounts to only 1.6Å. The 
sequence identities are 21% (overall) and 23% (TM domain), respectively. Thus, 
there is a very high level of 3D structure conservation in spite of low sequence 
homology. 
Similar to the suggested activation mechanism of rhodopsin, the conserved Trp6.48 in 
TM6 of the β2AR may serve as “toggle switch" that is involved in the transition 
between the inactive and the active state. A series of water molecules is also 
observed in both structures, extending from the binding site via the space between 
the helical bundle formed by TM2, 3, 6 and 7 to the cytoplasmic surface. 
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The location and the topology of the ligand binding sites as well as their hydrophobic 
nature are similar in the two structures, but the accessibility of the binding pocket 
from the extracellular side is significantly different. In rhodopsin, the covalently bound 
retinal is covered by a buried β-sheet in E2 ("cap" function) that effectively shields the 
ligand site from the extracellular compartment. In contrast, the E2 loop in the β2AR 
contains a short helix and is in a conformation that permits extracellular ligands to 
easily intrude into the binding site (Figure 5.2).  
 
 
Figure 5.2: Structure of the hβ2AR (left structure, T4L omitted) and rhodopsin (right structure). The 
structures are shown as cyan tubes, the E2 loops as red tubes. The ionic lock is represented by the 
two residues involved in the ionic interaction, and the “toggle switch” by Trp6.48. 
  
Compared to rhodopsin, the extracellular ends of TM3 and, in particular, TM1 are 
laterally more distant from the ligand binding site, while TM5 is slightly moved 
inwards. Another important difference is that the β2AR crystal structure does not 
contain the “ionic lock” formed by electrostatic interactions and hydrogen bonds 
E2 
E2 
Trp6.48 
toggle 
Ionic lock Ionic lock 
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between the cytoplasmic ends of TM3 and TM6 (Ballesteros et al., 2001). The ionic 
lock is known to be important for the stabilization of the inactive state of the receptor 
since point mutations of the interacting residues lead to constitutively active mutants 
(Kjelsberg et al., 1992; Lefkowitz et al., 1993). In the inactive conformation of 
rhodopsin the lock is closed with a distance of 2.9Å between Glu6.30 and Arg3.50. In 
the active state the ionic lock opens up (distance 4.1Å) (Salom et al., 2006). 
Surprisingly, this is also the case in both β2AR structures.although carazolol, an 
inverse agonist, is co-crystallized. The distance between the two conserved amino 
acids, Glu6.30 and Arg3.50, amounts to 6.2Å in the β2AR-T4L construct. However, 
differences between the intracellular ends of TM5 and TM6 as well as between the 
equivalent parts of I3 of the two β2AR structures indicate that these regions are 
probably artificial due to the adducts (T4L and Fab5, respectively) which specifically 
alter the topology of the cytoplasmic domain. Thus, no reliable conclusions about the 
native structure of this region can be drawn. 
 
5.3 Material and Methods 
 
5.3.1 Data set 
 
The 5-HT2A partial agonists considered and their biological data (Table 5.1) were 
obtained from Elz et al. (Elz et al., 2002; Heim et al., 1998; Heim et al., 2002; Pertz et 
al., 2000; Ratzeburg et al., 2003). The design of the series was based on a structural 
concept derived from SAR studies on diverse 5-HT2AR ligands (Elz et al., 2002; Heim 
et al., 2002). The 5-HT2AR agonistic activity of mostly less potent primary amines as 
5-HT, 3-(2-aminoethyl)quinazoline-2,4-dione, mescaline, and 1-(4-bromo-2,5-dimeth-
oxyphenyl)-isopropylamine (DOB) (Figure 5.1) was increased by a factor of 50 to 
2000 (Elz et al., 2002; Heim et al., 1998; Pertz et al., 2000). The most interesting 
derivatives showing partial agonistic activity were obtained by introduction of an 
ortho-methoxybenzyl substituent at the amine nitrogen and are up to 400-1400 times 
more potent than 5-HT.  
 
 
 
Chapter 5: Homology modeling of the 5-HT2A R based on the β2AR crystal structure 
 
 
 
75
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3: Primary amines with less potent 5-HT2AR agonistic activity 
 
5-HT2AR agonistic potency (pEC50) and intrinsic activity (efficacy, Emax) were 
measured by a functional in-vitro assay using cylindrical segments from rat tail 
arteries. The nature of the assay suggests that pEC50 values largely represent 
binding affinities since additional effects as transport and distribution do not play a 
major role. 
  
5.3.2 Fragment Regression Analysis (FRA) 
 
Fragment regression analysis was performed using the in-house program FRAREG. 
As an extension of the Fujita-Ban variant of simple Free-Wilson analysis, FRAREG 
permits more arbitrary fragmentations of the molecules and the multiple presence of 
a substituent in a given position. The definition of "pseudo fragments" reflecting 
interactions like intramolecular H bonds or steric hindrance is possible. The 
descriptors in the regression analysis are discrete 0-n variables. As result, the 
biological activity is decomposed into additive contributions of fragments and pseudo 
fragments. The FRAREG approach was applied to pEC50 (representing the 5-HT2AR 
agonistic potency) and log K* (representing the receptor activation). The derivation of 
K* values was based on a simple induced fit model: 
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Nr R1 R3 R4 pEC50 Emax Nr RN pEC50 Emax Nr R1 R2 RN/R3 R4 pEC50 Emax
5-HT OH H - 7.00 100 93 H 4.18 46 229 H H H Me 7.73 40 
199 H H H 6.39 26 94 Bz 4.84 33 230 Br H H H 9.66 35 
200 H H OH 6.87 47 181 CH2-2Thioph 5.47 22 231 Br H H Me 9.58 38 
201 H H OMe 6.81 44 304S Br H S-Me Me 9.32 26 
202 H H OEt 6.06 19 304R Br H R-Me Me 8.24 29 
203 H Me OMe 6.20 27 307 Br H N-Me Me 7.41 27 
204 OMe H H 7.00 30 
N
H
N
O
O
H
N
R3 R4
 234 Br Me H Me 8.10 20 
205 OMe H OH 7.50 38 Nr R3 R4 pEC50 Emax 235 I H H H 10.13 29 
206 OMe H OMe 7.08 54 157 H 2-Cl 5.08 15 236 I H H Me 10.09 30 
160 H 2-Br 5.05 16 305S I H S-Me Me 9.21 29 
166 H 2-Me 5.52 22 305R I H R-Me Me 8.41 28 
169 H 2-OMe 6.58 49 239 CF3 H H H 9.13 28 
OMe
OMe
R1
R2
NH2
 298S S-Me 2-OMe 6.26 41 240 CF3 H H Me 9.02 36 
Nr R1 R2  pEC50 Emax 298R R-Me 2-OMe 4.93 11 
211 H H  4.41 47 172 H 2-OEt 6.05 34 
41 Br H  7.20 58 173 H 2-NH2 5.05 54 
35 Br Me  7.99 71 177 H 2-OH 6.38 51 
H
N
R1 OMe  
36 I Me  8.13 68 Nr R1 pEC50 Emax
CH13 3-Br 6.90 38 
CH17 2-Br 6.62 26 
H
N
OR4
O
O
R2Br
 CH45 2,3,4-(OMe)3 7.66 50 
 
 
NH2
R1
 
Nr R2 R4 pEC50 Emax CH54 2,4,5-(OMe)3 8.14 57 
Nr R1 pEC50 Emax 270 H H 9.87 34 CH55 2,4,6-(OMe)3 8.78 49 
CH37 2,3,4-(OMe)3 5.88 59 271 H Me 10.15 27 KR5 3,4-(OMe)2 6.47 44 
CH52 2,4,5-(OMe)3 5.86 60 273 Me Me 8.33 17 KR12 3,5-(OMe)2 7.02 40 
CH51 4Br-2,4-(OMe)2 7.20 58 283 H H 9.94 24 KR22 2,6-(OMe)2 7.81 31 
 
 
with the aim to transform intrinsic activities into a logarithmic scale linearly related to 
the free energy of receptor activation. 
 
Table 5.1: Agonistic potency (pEC50) and intrinsic activity (Emax) of 5-HT2AR partial agonistic 
arylethylamines (indole, methoxybenzene and quinazolinedione derivatives) used in the study.  
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5.3.3 Generation of 3D structure models of 5-HT2A receptors 
 
For the construction of h5-HT2AR and r5-HT2AR homology models, the most complete 
crystal structure of the β2AR (β2AR-T4L, pdb ID 2rh1 (Cherezov et al., 2007)) was 
used as template after excision of the lysozyme adduct. The sequence of the β2AR 
was mutated into that of the h5-HT2AR at positions without gaps and deletions, i.e. 
TM1 to TM7, intracellular loops I1 and I2, and the C-terminus (C-Ter) up to Cys397, 
using the alignment shown in Figure 5.4. Since the 5-HT2AR N- and C-termini are 
longer than the N- and C-termini of the β2AR, and since the homology of the terminal 
sequences is low, the prediction of the chains preceding TM1 and following H8 would 
be highly speculative. Therefore, the first 69 N-terminal and the last 76 C-terminal 
residues were not considered in the construction of the models. 
The remaining intracellular and extracellular loops (E1, E2, E3 and I3) were filled by 
the Biopolymer loop search facility in Sybyl 7.3 (Tripos, St. Luis, MO) with 
appropriate segments from a binary protein database based on PDB structures as 
described in chapter 4. Side chains and hydrogens were added using the Biopolymer 
module of Sybyl 7.3. The model was initially relaxed with steepest descent 
minimization using the Amber FF99 force field, Amber FF99 charges and a distant 
dependent dielectric constant of 4, until the RMS gradient approaches 0.5 kcal mole-1 
Å-1 . During the first 100 cycles, the backbone was fixed. This initial optimization was 
followed by a Powell minimization (end RMS gradient 0.01 kcal mole-1 Å-1). To verify 
the integrity of the structure, as last step the optimized receptor model was submitted 
to 3D-Verify and Procheck  (Luthy et al., 1992) 
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B2AR      ---------------------------------MGQPGNGSAF---LLAPNRSHAPDHDVTQQR-  
h5HT2A    MDILCEENTSLSSTTNSLMQLNDDTRLYSNDFNS.EANTSD..NWTVDSE..TNLSCEGCLSPSC  
r5HT2A    MEILCEDNISLSSIPNSLMQLGDGPRLYHNDFNSRDANTSE.SNWTIDAE..TNLSCEGCLPPTC  
              
 
B2AR      ----DEVWVVGMGIVMSLIVLAIVFGNVLVITAIAKFERLQTVTNYFITSLACADLVMGLAVVPF 
h5HT2A    LSLLHLQEKNWSALLTAVVIILTIA..I...M.VSLEKKL.NA....LM...I..MLL.FLVM.V 
r5HT2A    LSILHLQEKNWSALLTTVVIILTIA..I...M.VSLEKKL.NA....LM...I..MLL.FLVM.V 
 
 
B2AR      GAAHILMK-MWTFGNFWCEFWTSIDVLCVTASIETLCVIAVDRYFAITSPFKYQSLLTKNKARVI 
h5HT2A    SMLT..YGYR.PLPSKL.AV.IYL...FS....MH..A.SL...V..QN.IHHSRFNSRT..FLK 
r5HT2A    SMLT..YGYR.PLPSKL.AI.IYL...FS....MH..A.SL...V..QN.IHHSRFNSRT..FLK 
 
 
B2AR      ILMVWIVSGLTSFLPIQMHWYRATHQEAINCYANETCCDFFTNQAYAIASSIVSFYVPLVIMVFV 
h5HT2A    .IA..TI.VGISMPIPVFGLQDDS---KVF-KEGS—-.LLA-DDNFVLIG.F...FI..T...IT 
r5HT2A    .IA..TI.VGISMPIPVFGLQDDS---KVF-KEGS—-.LLA-DDNFVLIG.F.A.FI..T...IT 
 
 
B2AR      YSRVFQEAKRQLQKIDKSEG-RFHVQNLSQVEQDGRTG--------------HGLRRSSKFCLKE 
h5HT2A    .FLTIKSLQKEATLCVSDL.T.AKLASF.FLP.SSLSSEKLFQRSIHREPGSYTG..TMQSISN. 
r5HT2A    .FLTIKSLQKEATLCVSDLST.AKLASF.FLP.SSLSSEKLFQRSIHREPGSYTG..TMQSISN. 
 
 
B2AR      HKALKTLGIIMGTFTLCWLPFFIVNIVHVIQD—-NLIR—-KEVYILLNWIGYVNSGFNPLIYCRS 
h5HT2A    Q..C.V...VFFL.VVM.C....T..MA..CKESCNEDVIGALLNVFV....LS.AV...V.TLF 
r5HT2A    Q..C.V...VFFL.VVM.C....T..MA..CKESCNENVIGALLNVFV....LS.AV...V.TLF 
 
 
B2AR      P-DFRIAFQELLCLRRSSLKAYGNGYSSNGN---TGEQSGYHVEQEKENKLLCEDLPGTEDFVGH 
h5HT2A    NKTY.S..SRYIQCQYKEN.KPLQLILV.TIPALAYKS.QLQMG.K.NS.QDAKTTDNDCSMVAL 
r5HT2A    NKTY.S..SRYIQCQYKENRKPLQLILV.TIPALAYKS.QLQVG.K.NSQEDAEQTVDDCSMVTL 
 
 
B2AR      QGTVPSDNIDSQGRNCSTNDSLL 
h5HT2A    GKQHSEEASKDNSDGVNEKV.CV 
r5HT2A    GKQQSEENCTDNIETVNEKV.CV 
 
 
Figure 5.4: Sequence alignment of the β2AR with 5-HT2ARs. Dots in the sequence indicate identity 
with the β2AR. Amino acids shown with grey shading represent the most conserved position in each 
TM. For the r5-HT2AR, the positions which differ from the h5-HT2AR are indicated in bold. 
 
5.3.4 Ligand selection, structure generation and docking 
 
The selection of one representative compound from each structural class – (1) 
indoles, (2) methoxybenzenes, (3) quinazolinediones – of 5-HT2AR partial agonistic 
arylethylamines was based on high potency and reproduction of all favourable ligand-
receptor interactions, also taking into account results from FRA. Among the 
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substituents at the amino moiety which were similarly varied in each subseries (see 
Table 5.1), a 2-methoxybenzyl group is optimal. Therefore each class was represen-
ted by a derivative containing this substituent. The selected compounds, 5OH-201 
(indole, additionally representing interaction of a 5-OH substituent like in 5-HT), 231 
(methoxybenzene) and 169 (quinazolinedione), are represented in Figure 5.5. 
 
Figure 5.5: Representative structures used for the docking studies 
 
The structures were constructed using Sybyl 7.3. All molecules were assumed to be 
protonated under physiological conditions. AmberFF99 atom types and Gasteiger-
Hückel charges were assigned to the ligands. Assuming that the ligands share a 
common binding site at the receptor, a structure-based alignment was to be 
achieved. I.e., the docking modes (bioactive conformations) must rely on informa-
tions about the location of putative binding site residues. Site-directed mutagenesis 
studies, as already described in Chapter 4, indicate that the highly conserved 
Asp1553.32 (Sealfon et al., 1995; Wang et al., 1993), the serines Ser1593.36, 
Ser2395.43, Ser2425.46 (Ala242 in r5-HT2AR) (Johnson et al., 1994) and the 
phenylalanines Phe2435.47, Phe2445.48, Phe3406.52 (Choudhary et al., 1993; 
Choudhary et al., 1995) are important for binding and efficacy of agonists and partial 
agonists at the 5HT2AR. The three ligands were manually docked into the binding site 
considering the mutagenesis data and the QSAR obtained from fragment regression 
analysis. During docking, the conformation of the ligands was varied in order to get 
maximal overlap of the scaffolds and shared interactions with the essential amino 
acids described above. The complexes were optimized by a stepwise approach: (1) 
50 cycles AmberFF99 force field with fixed ligands (distant dependent dielectric 
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constant 4, steepest descent method), (2) subset minimization of the ligand and a 
receptor region 6 Å around using the combined protein-ligand force field MMFF64 
(distant dependent dielectric constant 1, Powell method) up to an RMS gradient of 
0.05 kcal mole-1 Å-1), (3) AmberFF99 force field with fixed ligands (distant dependent 
dielectric constant 4, Powell method, final RMS gradient 0.01 kcal mole-1 Å-1). Range 
constraints were occasionally applied between Asp1553.32 and the protonated 
nitrogen of the ligands, additionally for cpd. 231 between Ser1593.36 and the 2-OCH3 
group, and for cpds. 5OH-201 and 231 between Ser2395.43 and the 5-OH and 5-
OCH3 group, respectively. 
 
5.3.5 3D QSAR Approaches: CoMFA and CoMSiA 
 
A common structure-based alignment of the whole series was obtained by 
adjustment of the conformations according to the template of the respective structural 
class (cpds. 169, 5OH-201, 231), followed by minimizations with the template forcing 
method (multifit in Sybyl 7.3). CoMFA (Cramer et al., 1988b) and CoMSIA (Klebe et 
al., 1994) approaches were performed with the QSAR module of Sybyl 7.3. The grid 
size was set to 2.0 Å. In CoMFA, the steric and electrostatic fields were calculated 
using the default probe atom, C.3+, and cutoff of the energies at 30 kcal/mole. In 
CoMSIA, the steric, electrostatic, hydrophobic, and hydrogen bond donor and 
acceptor fields, based on interactions of the molecules with a common probe atom 
(radius 1 Å, charge +1, hydrophobicity +1, H bond donor and acceptor properties +1), 
were considered with an attenuation factor α of 0.3. 
For correlation of pEC50 values with the CoMFA and CoMSIA field variables, Partial 
Least Square (PLS) models (Wold et al., 1984) were generated by the QSAR module 
of Sybyl 7.3. Different cross-validation variants (Cramer et al., 1988a), leave-one-out 
and leave-ten-out (10 runs), were applied to obtain predictive models and to 
determine the optimal number of components according to the lowest standard error 
of prediction (sPRESS).  
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5.4 Results and Discussion 
 
5.4.1  Fragment Regression Analysis 
 
 "Additivity models" based on indicator variables and calculated by Free-Wilson 
analysis or FRA are well suited preliminary tools to obtain concise, easily 
interpretable QSAR results. To a certain degree, these approaches also check the 
coherence of the biological data and the congenerity of the series and allow the 
recognition of outliers. For the present FRA of pEC50 and log K* values, 2-
phenethylamine was defined as basic structure whose contribution is represented by 
the intercept of the regression equation. The series has been simplified in a general 
structure shown in Figure 5.6. 
 
 
 
 
 
 
 
 
Figure 5.6: Basic structure, fragmentation and main fragments  
 
The results are shown in Table 5.2. The FRA of pEC50 explains 95.7 % of the data 
variance. The high correlation is also due to the large range of pEC50 values. The 
residual standard deviation of 0.49 is of acceptable size compared to the experi-
mental error. The basic phenethylamine with a contribution of only 3.45 provides a 
scaffold for activity enhancing substitutions and modifications. The larger aromatic 
systems (indole, quinazolinedione) increase pEC50 by ca. 1 log unit. The striking and 
nearly additive effect of methoxy substituents at the indole (5-OMe) and the phenyl 
moiety is congruent with the high contribution of the benzodifuran moiety. It can be 
suggested that at least one oxygen atom is involved in a polar interaction with the 
receptor.  
The second striking result is the large contribution of lipophilic substituents like 
halogens and CF3 in para position of phenethylamine derivatives (1.9 to 2.9 pEC50 
units), indicating fit to a specific hydrophobic site. 
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Table 5.2: Results of the fragment regression analysis, FRA, of pEC50 and log K* 
Pos. Fragment pEC50 log K* 
  increment 95% conf.int.1 increment 95% conf.int.1 
Intercept (basic structure) 3.45 ±1.62 *** -0.07 ±0.66 
Ar Phenyl 2 0  0  
 Indolyl 1.36 ±1.46 * 0.19 ±0.60 
 Quinazolinedione 0.94 ±1.61 0.25 ±0.66 
 Benzodifuranyl 1.89 ±1.60 ** -0.16 ±0.66 
 2OMe 0.97 ±1.14 * -0.01 ±0.47 
 3OMe 0.64 ±1.13 0.05 ±0.46 
 4OMe 0.77 ±0.74 ** 0.26 ±0.30 * 
 5OMe 0.79 ±0.70 ** 0.12 ±0.29 
 6OMe 1.61 ±1.16 *** 0.08 ±0.48 
 2Br 1.29 ±1.85  -0.07 ±0.76 
 3Br 1.57 ±1.85 * 0.17 ±0.76 
 4Br 2.44 ±0.81 *** 0.08 ±0.33 
 4I 2.93 ±0.85 *** 0.09 ±0.35 
 4CF3 1.91 ±1.01 *** -0.05 ±0.42 
R2 H 2 0  0  
 Me -0.61 ±0.67 * -0.05 ±0.27 
RN H 2 0  0  
 Benzyl 1.14 ±0.83 *** -0.56 ±0.34 *** 
 CH2-thiophenyl 1.08 ±1.19 * -0.74 ±0.49 *** 
 2OH 0.89 ±0.74 ** 0.23 ±0.31 
 2OMe 0.74 ±0.73 ** 0.24 ±0.30 * 
 2OEt 0.31 ±0.95 -0.05 ±0.39 
 2Me -0.02 ±1.23 -0.18 ±0.50 
 2Cl -0.46 ±1.23 -0.38 ±0.50 
 2Br -0.49 ±1.23 -0.35 ±0.50 
 2NH2 -0.49 ±1.23 0.44 ±0.50 * 
 (R)-Me -1.41 ±0.72 *** -0.40 ±0.30 *** 
 (S)-Me -0.38 ±0.65 -0.18 ±0.27 
 N-Me -2.12 ±1.14 *** -0.24 ±0.47 
      
  r 0.978 r 0.869 
  r2 0.957 r2 0.755 
  s 0.492 s 0.202 
  F 20.64 *** F 2.84 *** 
1 Significance levels for t-tests of the increments: * >90%, ** >95%, *** >99%. 2 Fragment belonging to 
the basic structure (contribution included in the intercept). 
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On average, methyl groups in α-position of the ethyl side chain decrease activity. 
However, the effect of α-Me depends on RN: if one considers the pEC50 values and 
residuals, it becomes obvious that the methyl branch is favourable in primary amines 
and unfavourable in secondary benzylamines. This different behaviour may be simply 
due to a potential interaction of the α-Me group with the receptor which is not 
possible in the case of a bulky RN moiety because of restricted degrees of freedom 
for fit. A methyl group as part of a tertiary amine strongly lowers activity.  
It is well known that aralkyl groups as RN substituents lead to high affinity of agonists 
and antagonists for many biogenic amine receptors. Corresponding to this quite 
general rule, secondary benzylamines are more than one pEC50 unit more active at 
the r5-HT2AR than their NH2 analogs. An ortho-OH or -OMe substituent at the phenyl 
ring further increases activity, so that the contribution of 2-OMe- or 2-OH-benzyl 
groups approaches 2 log units. The effect of other ortho substituents is not 
significant. It may be suggested that the oxygen is involved in a polar interaction with 
the receptor. Among the stereoisomeric methylbenzyl groups, the S isomer is 
equiactive compared to benzyl, whereas the R configuration leads to reduction of the 
activity by nearly 1.5 pEC50 units. 
There is no real outlier in the FRA of pEC50 even when the weak criterion 
abs(residual) > 2s is applied. However, eight compounds cannot be validated 
because of unique substituents (residuals of 0). Three of the four largest residuals 
are due to the different α-Me effect (see above). The fourth "outlier“ is the "simple" 
2,5-dimethoxyphenethylamine, whose activity is by 0.8 pEC50 units lower than 
calculated. 
The analysis of log K* should provide some detailed information about structure-
efficacy relationships on a scale which closely represents the free energy of receptor 
activation. However, this approach suffers from the low standard deviation of the 
dependent variable (range of log K* from -0.91 to 0.39, s = 0.29). The FRA model 
explains 75% of the variance. 
Therefore, conclusions from the analysis are restricted to some more pronounced 
effects. The contribution of 2-phenethylamine as basic structure is about zero 
corresponding to an intrinsic activity of 50%. Larger aromatic systems (indole, 
quinazolinedione) and methoxy substituents (except 2-OMe) only slightly increase 
log K*. No contribution is significantly different from zero at the 95% level. It seems 
that all arylethylamine moieties except those with a benzodifuranyl group are 
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approximately equipotent in their ability to induce the transition from the inactive to 
the active receptor state. In the present series of partial agonists, appropriate 
substitution can improve this potential by only 0.3 log K* units. 
Strikingly, log K* is significantly reduced in the case of the secondary amines. The 
same groups (benzyl, CH2-2-thiophenyl) which strongly increase pEC50 reduce the 
intrinsic activity. This effect may be slightly counterbalanced by ortho benzyl 
substituents (OH, OMe, NH2), indicating the role of polar interactions at this position 
also for receptor activation. On the other hand, ortho-halogen substitution is 
unfavourable. Generally, the gain in affinity by the bulky benzyl group is 
accompanied by a loss of the ability to activate the receptor, possibly due to reduced 
flexibility of the complex. 
All these results and suggestions have been used, together with informations from 
the mutagenesis data, for the derivation of the putative human and rat 5-HT2AR 
binding site and have been confirmed with the docking studies (see also Chapter 4). 
 
5.4.2 Comparison between 5-HT2AR models derived from β2AR and from 
bovine rhodopsin 
 
Needless to say that the differences between the crystal structures of bovine 
rhodopsin and the β2 adrenoceptor mentioned above are also found in the 
corresponding models. The degree of homology between the 5-HT2AR and the β2AR 
is much higher than between the 5-HT2AR and rhodopsin (32.2% vs 19%), and also 
the ligands of the two biogenic amine GPCRs are mutually similar, but different to 
retinal. Thus, the β2AR should be a more suitable template for 5-HT2AR and, in 
particular, ligand binding site models than rhodopsin. 
In both the β2AR and the rhodopsin based models of the 5-HT2AR the packing of the 
seven TM helices is conserved. The secondary structure of the receptor is composed 
of seven TM domains (TM1-TM7) connected by three intracellular (I1-I3) and three 
extracellular loops (E1-E3), a truncated N-termius and the helical portion (H8) of the 
C-terminal domain. The conformations of the E2 loops differ depending on the 
template (Figure 5.7). E2 is constrained by a disulfide bridge between Cys148 and 
Cys272 in both models, but inserted into the membrane bilayer only in the case of 
the model derived from rhodopsin. In the β2AR based model the E2 conformation is 
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more open towards the extracellular side so that the ligand may easily intrude into 
the binding site. The E2 loop of the β2AR contains a small α-helix that is probably not 
present in the 5-HT2AR. The length of this loop in the β2AR and the 5-HT2AR differs 
by 4 amino acids (22 and 18 residues, respectively). Moreover, the β2AR shows a 
second, intra-E2 disulfide bond between Cys184 and Cys190 which stabilizes the 
helical conformation. Together these differences argue against corresponding α-
helices in both biogenic amine GPCRs. 
 
 
Figure 5.7: Side view of the 5-HT2AR models derived from the β2AR (left) and bovine rhodopsin 
(right) crystal structures. In orange are shown TMs 4 and 5 connected by E2 (green).  
 
The rhodopsin crystal structure and the models derived from it contain a number of 
interhelical contacts that are predicted to stabilize the TM domains in the inactive 
state of the receptor and that presumably play a functional role in the receptor 
activation (see Chapter 4). In the β2AR based model, most of these contacts are not 
present (see Table 5.3).  
5-HT2A model derived from β2AR 5-HT2A model derived from rhodopsin 
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Table 5.3: Comparison of interhelical interactions in the 5-HT2AR models derived from bovine 
rhodopsin and β2AR crystal structures 
Domain Residues Min. distance (Å)* 
  5-HT2AR1 5-HT2AR2 
TM1-TM3 Asn921.50  - Asp1202.50 2.45 4.20 
TM3 Arg1733.50 - Asp1723.49 2.11 2.37 
TM3-TM6 Arg1733.50 - Glu3186.30 1.95 9.10 
TM7-TM2 Asn3767.49 - Asp1202.50 2.04 5.10 
TM7 Asn3767.49 - Ser3737.46 3.65 7.16 
1 Model derived from bovine rhodopsin 
2 Model derived from β2AR 
*   Distance between the nearest heavy atoms of interacting residues 
 
As already mentioned, the long distance between Arg1733.50 and Glu3186.30 is probably 
artificial due to the T4L adduct in the β2AR template. However, typical interactions 
suggested to be responsible for the inactive state in analogy to rhodopsin are 
replaced by other contacts, some of them mediated by water molecules. E.g., 
Asn921.50 interacts via water with Asn3767.49 and directly with Ser3737.46, Thr881.46 
and Ile961.54; Asp1202.50 interacts with Asn3767.49, Gly1242.54 and via a water 
molecule with Ser3727.45; Asn3767.49 interacts with Tyr3807.53, and Ser3737.46 with 
Tyr3707.43 supposed to be involved in ligand binding.  
Also the open conformation of E2 is stabilized by a network of polar interactions. The 
side chain of Ser119 interacts with the side chain of Asp232, the side chain of 
Asp218 with the side chain of Lys223, and the backbone of Phe222 with the side 
chain of Lys220 and with the backbone of Ser226. 
Looking at the binding site of the two receptor models (Figure 5.8) there are no 
significant differences. The position of the residues is similar in both models, but the 
binding site of the β2AR based model is slightly shifted to the left due to the different 
position of some TM domains, in particular TM3 and TM5. Therefore the binding 
mode of the ligands should largely correspond to that suggested from 5-HT2AR-partial 
agonist complexes based on the rhodopsin template (see Chapter 4). 
 
 
 
 
 
 
 
Chapter 5: Homology modeling of the 5-HT2A R based on the β2AR crystal structure 
 
 
 
87
 
Figure 5.8: Binding site superposition of the h5-HT2AR models derived from β2AR (green) and from 
bovine rhodopsin (magenta). A. Representation of the residues involved in polar interactions with the 
ligands. B. Representation of the two hydrophobic pockets involved in interactions with aromatic 
moieties of the ligands. 
 
5.4.3 Docking of representative partial agonists  
 
 As representative 5-HT2AR partial agonists of the arylethylamine series the 
compounds 5OH-201 (indole), 231 (methoxybenzene) and 169 (quinazolinedione) 
were selected (see Figure 5.5). Without consideration of the 5-hydroxy group added 
to cpd. 201, the contributions of the three aryl fragments to pEC50 differ by only ca. 
0.8 orders of magnitude (see Table 5.2). Furthermore, the effects of a 5-methoxy 
group at the aryl moiety and of a benzyl group as RN is similar in each structural 
A. 
B. 
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class. Therefore an overlapping binding mode of the different partial agonists is likely 
which can be derived from the docking of the three ligands into the 5-HT2AR model. 
Figure 5.9 shows the complexes of the r5-HT2AR with the representative compounds 
5OH-201, 231 and 169, respectively, after energy optimization. 
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Figure 5.9: View of the r5-HT2AR model from the extracellular side, in complex with cpds. 5OH-201 
(A), 231 (B) and 169 (C). The putative agonist binding site (C atoms of amino acids in cyan and red, 
respectively) and the three α helices (TM3 in green, TM5 in orange and TM6 in yellow) are shown. 
The amino acids in red represent hydrophobic pockets interacting with the ligands. The white dotted 
lines represent specific polar interactions.  
 
In accord with the general analogy of the binding sites (see Figure 5.8), the important 
interactions of the three compounds with the β2AR based r5-HT2AR model are similar 
to those suggested from the receptor model derived from bovine rhodopsin (for 
detailed discussion, see Chapter 4), and can be summarized as follows: 
- The arylethylamine moieties interact with three sites: (1) Asp1553.32 forming a salt 
bridge with the cationic amine, (2) a hydrophobic pocket comprising Phe2435.47, 
Phe2445.48 and Phe3406.52, as well as (3) Ser1593.36 and Ser2395.43 as possible H 
bond acceptors or donors. 
- Strongly potency increasing halogen substituents in para-position of dimethoxy-
phenyl compounds (cpd 231, Figure 5.9 B) and the phenyl moiety of 
quinazolinedione derivates (cpd.169, Figure 5.9 C) project onto the hydrophobic 
pocket formed by Phe2435.47 and Phe2445.48. 
- Ser1593.36 may interact with the indole NH, one of the the quinazolinedione 
oxygens and with the 2-OMe group of dimethoxyphenyl compounds. In the h5-
HT2AR, Ala2425.46 of the rat species is mutated into Ser2425.46 which is possibly 
involved in H bonds with these groups, too.  
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- 5-OH and 5-OMe substituted indoles and 2,5-dimethoxyphenethyl compounds are 
able to form H bonds with Ser2395.43. Thus, bidentate polar interactions of aryl 
moieties are possible in the case of these derivatives, whereas quinazolinediones 
probably form only one H bond. 
- The benzyl substituent (RN) interacts with a second hydrophobic pocket consisting 
of aromatic residues around Phe3396.51 (Trp3677.40 and Tyr3707.43). 
- Since an oxygen in ortho-position of the benzyl group (2-OH, 2-OMe) further 
enhances activity, an additional interaction with a hydrogen donor, possibly via 
water, may be suggested. In contrast to the models based on rhodopsin, 
Asn3436.55 is too far away from these substituents for direct interaction. 
5.4.4 3D-QSAR models 
 
CoMFA and CoMSIA techniques were used to study quantitative structure-activity 
relationships of the 5-HT2AR partial agonists at the three dimensional level. The 
pEC50 values were used as the dependent variable. The most crucial step in 3D 
QSAR approaches is to generate an alignment that represents the active 
conformation of the compounds. Most reliable is a structure-based alignment, using 
the three compounds in the conformations obtained from the docking studies as 
templates (Figure 5.10).  
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Figure 5.10: A. Binding conformation and alignment of compounds 169, 5OH-201 and 231;                          
B. Superposition of all compounds used in 3D QSAR analysis 
 
Figure 5.10 also shows the resulting alignment of all compounds from Table 5.1 
(except 181 because of the unique thiophenyl group) used for the 3D QSAR 
approaches.  
The results of the PLS analyses of the dependence of pEC50 on the field variables 
from CoMFA and CoMSIA are summarized in Table 5.4.   
 
Table 5.4: CoMFA and CoMSIA results 
 
Leave-one-out Leave-ten-out Final model Analysis Fields 
q2 sPRESS PCs q2 sPRESS PCs r2 s PCs
CoMFA SE 0.716 0.922 4 0.700-0.788 0.890-1.043 4-10 0.858 0.651 4 
CoMSIA SEHA 0.807 0.752 3 0.763-0.809 0.767-0.957 3 (4) 0.873 0.610 3 
Field contributions: CoMFA S : 0.80, E: 0.20. CoMSIA S: 0.16, E: 0.19, H: 0.47, A: 0.18 
                                  Fields: S – steric, E – electrostatic, H – hydrophobic, A – H bond acceptor     
 
The CoMFA model, based on steric and electrostatic field variables, resulted in a 
cross-validated q2 of 0.716 at the first minimum of sPRESS, indicating an optimal 
number of four principal components (PCs). However, there was a second, even 
lower sPRESS minimum at 10 PCs. Whereas the leave-ten-out cross validation 
generally confirmed the good predictivity of the model, the optimal number of PCs 
varied from 4 to 10. Using a large number of PCs increases the complexity and adds 
more details, but enhances the risk of "explaining noise" by low-variance PCs. It 
appears that the higher PCs depend on the least potent compounds (pEC50 < 5) 
since omission of these derivatives consistently led to three-component models. 
B. 
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Possibly the low activity of some 5-HT2AR partial agonists is additionally due to other 
reasons than weak affinity (reasons that rely on the in-vitro organ assay). It is 
therefore appropriate to stop the inclusion of PCs at the most trusted number, i.e., 
four, even if some "compound specific" effects on the potency are not contained in 
the non-crossvalidated model. The final PLS analysis with four PCs explains 86% of 
the data variance, corresponding to a residual error of 0.651. This model is mainly 
based on the steric interactions of the ligands with the r5-HT2AR, the contribution of 
the electrostatic field amounts to only 20%.  
CoMSIA approaches considered the steric, electrostatic, hydrophobic, H-bond 
acceptor and H-bond donor fields. The latter one was excluded in the final models 
because of the marginal contribution to the explained data variance. Leave-one-out 
crossvalidation resulted in a slightly better predictive power than with CoMFA (q2 
0.807 vs. 0.716), and the optimal number of PCs was reduced to three. Also in this 
case, the leave-ten-out approaches were quite consistent. In contrast to CoMFA, the 
number of PCs varied only between three and four. The final PLS model accounts for 
87% of the data variance (residual error 0.610). The contribution of the electrostatic 
field is about the same as in CoMFA. However, the steric effects representing 80% of 
the CoMFA model are now partitioned into a main, hydrophobic fraction (47%) and 
additional H-bond acceptor and "pure" steric components (ca. 18%). 
An advantage of CoMFA and CoMSIA is the possibility to visualise the field effects 
on the biological activity as 3D contour plots. This graphical representation is helpful 
to identify the regions where structural modifications can affect the potency of the 
compounds. Moreover, structure-based alignments enable to project the contour 
plots onto the underlying receptor model, suggesting which ligand-receptor inter-
actions account for the QSAR. Thus, the following CoMFA and CoMSIA plots are 
drawn inside the putative r5-HT2AR binding site, taking the models with the three 
representative compounds as reference (cp. Figs. 5.9 and 5.10). . 
The isocontour plots of the steric and electrostatic field contributions obtained from 
CoMFA are drawn together with exemplary ligands and the active site of the r5-
HT2AR in Figure 5.11. These maps show regions where differences in molecular 
fields are associated with differences in the biological activity.  
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Figure 5.11: CoMFA contour maps projected into the r5-HT2AR binding site. A. Contribution of the 
steric field, docking of cpd. 231: green – bulk increases potency, yellow – bulk decreases potency.. B. 
Contribution of the electrostatic field, docking of cpd. 206: red – negative charge increases potency, 
blue – positive charge increases potency. 
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In Figure 5.11 A., the 2,5-dimethoxyphenyl derivative 231 is displayed. The green 
and yellow regions around the halogen substituent in para position of the phenyl ring 
point into the pocket of mainly aromatic amino acids in TM5. This pocket is narrowed 
and may optimally interact with p-Br and p-I substituents. The introduction of a benzyl 
substituent at the protonated nitrogen significantly increases the activity. This effect is 
reproduced by the green regions close to the benzyl moiety. The yellow contours 
along the alkylamine chain probably reflect the largely unfavourable influence of 
methyl branches and the potency differences between (R)- and (S)-methylbenzyl 
derivatives (distomers and eutomers, respectively)..  
In Figure 5.11 B., the electrostatic contour map is displayed together with the indole 
206. The red contour close to the 5-methoxy group indicates that a negative charge 
is favourable in this position, suggesting a H bond with Ser2395.43 as modeled in the 
docking studies. The blue region around the indolic nitrogen is in agreement with its 
role as H bond donor, probably for Ser1593.36. However, the arrangement of the blue 
and red contours below the indole moiety do not correspond to interactions of 
quinazolinedione derivatives with this residue. The contributions of indole and 
quinazolinedione fragments to pEC50 are similar (see FRA results), so that in both 
cases one H bond with the r5-HT2AR can be assumed. It will be shown below that the 
separation of electrostatic and H bond acceptor fields in CoMSIA is better suited to 
predict structural effects in more detail. The small red contours at the benzyl group 
indicate the favourable influence of 2-hydroxy or 2-methoxy substituents. That 
positive charges around the benzyl moiety increase the potency (blue region) might 
be due to electron-withdrawing effects of those groups. 
The isocontour plots of the steric, electrostatic, hydrophobic and H-bond acceptor 
field contributions resulting from CoMSIA are drawn together with representative 
ligands and the active site of the r5-HT2AR in Figures 5.12 – 5.15. The effects of the 
steric fields on pEC50 (Fig. 5.12) largely correspond to the CoMFA results in spite of 
the much lower overall contribution to the model (16% vs. 80% in CoMFA). The 
green regions around the benzyl and the aryl moieties indicate optimal fit into the 
binding site with some degrees of freedom for larger rings or substituents in 6-
position of phenethylamines.  
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Figure 5.12: CoMSIA contour map of the steric field contribution projected into the r5-HT2AR binding 
site, docking of cpd. 231: green – bulk increases potency, yellow – bulk decreases potency. 
 
The contributions of the electrostatic fields to pEC50 (Fig. 5.13) are more distinct than 
in the case of the CoMFA approach. The favourable effect of negative charges 
around the aryl moiety corresponds to the increase in potency caused by methoxy 
and halogen substituents in 2-, 4-, 5- and 6-position of phenethylamines and by the 
oxygens of quinazolinediones. Accordingly, the CoMSIA model suggests the role of  
Ser1593.36 and Ser2395.43 as H bond donors. However, the blue region close to the 
indole nitrogen, present in the electrostatic field contributions from CoMFA (see Fig. 
5.11) and assumed to reflect an H bond with Ser1593.36 as acceptor, is missing. At 
the benzyl moiety, the negative charge of, in particular, 2-hydroxy and -methoxy 
substituents is favourable. 
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Figure 5.13: CoMSIA contour map of the electrostatic field contribution projected into the r5-HT2AR 
binding site, docking of cpd. 231: red – negative charge increases potency, blue – positive charge 
increases potency. 
 
In some respects, the contributions of the hydrophobic (Fig. 5.14) and the steric fields 
to pEC50 complement one another. Taking into account that the overall contribution of 
hydrophobicity predominates in CoMSIA (47% vs. 16% of the steric fields), the effect 
of, e.g., halogen substituents in para position of phenethylamines is mainly of 
lipophilic nature, emphasizing that interaction with a hydrophobic pocket formed by 
Phe2435.47, Phe2445.48 and Phe3406.52 is possible. In other positions of the phenyl 
ring and in corresponding regions of quinazolinediones, polar groups whose 
contributions are also represented by the electrostatic fields are favourable (red 
contours in Fig. 5.14). The role of a benzyl group for high potency is reflected by 
hydrophobicity, too. 2-substituents at this moiety are surrounded by a "polar" region, 
again indicating that electronic effects predominate in this position. 
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Figure 5.14: CoMSIA contour map of the hydrophobic field contribution projected into the r5-HT2AR 
binding site, docking of cpd. 231: orange – hydrophobic groups increase potency, red – hydrophobic 
groups decrease potency. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.15: CoMSIA contour map of the H-bond acceptor field contribution projected into the r5-
HT2AR binding site, docking of cpd. 169: magenta – H-bond acceptor groups increase potency, red – 
H-bond acceptor groups decrease potency.  
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The contributions of the H-bond acceptor fields to pEC50 (Fig. 5.15) must be analyzed 
together with the electrostatic efffects (Fig. 5.13). The magenta contour surrounding 
the methoxy substituents in ortho-position of the benzyl group again indicates the 
capability of this group to form an H bond with the receptor (possibly via a water 
molecule). However, this effect is in parallel with the potency increasing influence of 
a negative charge in the electrostatic field contributions so that the nature of the 
interaction is in question. On the other hand, the red contours at the aryl moiety, 
corresponding to unfavourable effects of H bond acceptor properties just in the case 
of the quinazolinedione oxygens, seem to counterbalance the role of negative 
charges in this region (see Fig. 5.13). Thus, the effects of the aryl systems on r5-
HT2AR agonistic activity are quite subtle, and the different field contributions cannot 
be simply separated into definite modes of interaction.   
 
5.5 Conclusions 
 
In this study, two 3D QSAR approaches, CoMFA and CoMSIA, have been used to 
predict the partial agonistic activity of a series of 50 5-HT2AR ligands. The set 
contains three different structural classes of compounds and presents a large 
variability of the pharmacological data. The recent crystal structure of the human 
β2AR has been used to generate 5-HT2AR models by homology modeling. Based on 
in-vitro mutagenesis data and on a preliminary fragment regression analysis of the 
partial agonistic potency, docking studies of representative ligands have led to the 
identification of putative bioactive conformations, to suggestions about important 
interactions with amino acids of the binding site and to a structure-based alignment of 
the whole series. The models derived from the 3D QSAR approaches are compatible 
with the docking studies and indicate which effects account for the activity of the 
compounds considered.  
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in different active states and of 
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6.1 Introduction 
 
The binding of agonists stabilizes or induces active states of GPCRs, representing 
specific conformations which are recognised by heterotrimeric G-proteins through 
interactions with the intracellular domains. Analysis of several GPCR mutants has 
indicated that the transmembrane (TM) pocket close to the extracellular region forms 
the binding site for cationic biogenic amine ligands, while the intracellular loops 
mediate receptor-G-protein coupling (Strader et al., 1994). Changes in certain TM 
positions lead to constitutively active receptor mutants, CAMs (Robinson et al., 1992; 
Scheer and Cotecchia, 1997), whereas other mutations generate uncoupling 
mutants, UCMs, that bind agonists, but fail to activate G proteins (Monnot et al., 
1996; Strader et al., 1988). Some mutations affect agonist, but not antagonist binding 
(Wess et al., 1991), and vice versa (Heitz et al., 1999). These findings and the 
observation of rigid-body motions of the TMs (Farrens et al., 1996; Resek et al., 
1993) in the photoactivation process of rhodopsin suggest the presence of multiple 
conformational states in inactive and active GPCRs. Whereas the recent crystal 
structures of the human β2-adrenoceptor provide direct information on the 3D 
structure of inactive GPCR states, there are still no homologous templates represen-
Chapter 6: Modeling of the 5-HT2A receptor in different active states 
 
 
 
104 
ting active GPCR conformations. However, conclusions can be drawn from analogies 
with the respective states of rhodopsin. The photochemical isomerisation of the 
retinylidene chromophore transfers rhodopsin, a class A GPCR, from the inactive to 
the active form, metharhodopsin II, through a number of photointermediates: 
bathorhodopsin, lumirhodopsin, metarhodopsin I, metarhodopsin I380, metarhodopsin 
Ib (Figure 6.1). The activation process comprises several steps corresponding to 
different states of receptor activation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1: The photocascade of rhodopsin photointermediates. Rhodopsin binds the 11-cis 
retinylidene chromophore which isomerizes to the all-trans chromophore in bathorhodopsin. Neutrali-
zation of the Schiff base (PBS) occurs under physiological conditions during the lumirhodopsin to 
metarhodopsin I380 transition, or at low temperatures during the metarhodopsin Ib to metarodopsin II 
transition. The UV absorption maximum for each of the photointermediates is indicated in parenthesis. 
 
The structural changes of the receptor photointermediates during the activation 
process has been suggested from FTRI (Ohkita et al., 1995), NMR (Feng et al., 
2000), CD (Shichida et al., 1978; Waggoner and Stryer, 1971) mutagenesis 
(Struthers et al., 2000) and molecular modeling studies (Choi et al., 2002; Ishiguro, 
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2004; Ishiguro et al., 2003; Ishiguro et al., 2004). All these studies indicate that the 
arrangement of TMs 1, 2, 5 and 7 is not strongly affected by the conversion of 
rhodopsin to metarhodopsin II. In particular, TMs 1, 2, and 7 remain unchanged 
during the activation process because of the stability of an H-bond network formed by 
conserved residues and a hydrophobic core consisting of residues at the intracellular 
ends of the three TMs and in helix 8. However, TMs 3, 4 and 6 move away from their 
positions in the rhodopsin structure, the largest displacements occuring in the 
cytoplasmic face of the receptor. During photoactivation and cis-trans isomerisation 
of retinal, TM3 is forced outwards probably as result of steric interactions with the 
chromophore. This initial motion corresponds to the formation of the first, instable 
photointermediate, bathorhodopsin. Lumirhodopsin and metarhodopsin I380 result 
after a subsequent swing of the C-terminal end of TM3 and a following movement 
and partial rotation of the N-terminal part of TM4. The complete activation of the 
receptor, corresponding to metarhodopsin II, is caused by a counter-clockwise 
rotation (ca. 100°) of TM6 around the axis of its N-terminal end and a translation of 
TM6 towards TM3. 
As described above, the motions of the transmembrane segments lead to different 
receptor structures with specific functions. Metarhodopsin I does not bind the G 
protein transducin and is thus totally inactive, whereas the subsequent intermediate, 
metarhodopsin Ib, binds but does not activate transducin (Sakmar, 1998; 
Tachibanaki et al., 1997). The photoisomerization of the retinylidene chromophore 
induces the motion of TM3 and TM4 and the formation of the next intermediates. The 
initial movement of these helices appears to be insufficient for interactions of the 
second intracellular loop (I2) with transducin. The structure of metarhodopsin I380, 
photointermediate in the alternative pathway to metarhodopsin II, is suggested to be 
analogous to a rhodopsin mutant with higher constitutive activity than opsin (Ishiguro, 
2004; Robinson et al., 1992). This mutant, although only partially active, exhibits full 
activity upon binding of exogenous all-trans retinal. Thus, the mutant structure is 
expected to resemble a receptor state stabilized by partial agonists, and the 
formation of the fully active form is thought to involve rotational motion of TM6.  
Let us assume that three of the photointermediates in the rhodopsin photocascade, 
rhodopsin, metarhodopsin I380, and metarhodopsin II, correspond to individual GPCR 
states, namely an inactive, a partially active, and a fully active state, representing the 
binding of antagonists, partial agonists and agonists, respectively (Figure 6.2). Then 
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it should be possible to extend the results obtained for the interaction of ligands with 
the inactive state of the h5-HT2AR (based on rhodopsin, see Chapter 4). The aim of 
the present chapter is to derive homology models of partially active and fully active 
h5-HT2AR states, to analyze their characteristic features, and to perform docking of 
representative partial agonists and agonists. 
 
 
 
Figure 6.2: The supposed three binding states of the receptor, rhodopsin (inactive state), 
metarhodopsin I380 (partially active state), and metarhodopsin II (fully active state), involved in the 
binding of functionally distinct ligands, antagonists, partial agonists, and agonists respectively.  
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6.2 Material and methods 
 
6.2.1 Model construction 
 
3D models of the human 5-HT2A receptor (h5-HT2AR) were generated by homology 
modeling using the structures of bovine rhodopsin in two different states of activation 
as template. The structures were produced by Dr. M. Ishiguro from Suntory Institute 
for Bioorganic Research, Osaka, and kindly handed to our laboratory for this study 
(Figure 6.3).  
The sequence of the bovine rhodopsin templates was mutated into the corresponding 
sequence of the h5-HT2AR at positions without gaps and deletions using the same 
alignment as obtained from the Fugue approach in Chapter 4 (Figure 6.4). The 
remaining intracellular and extracellular loops (E2, I2, I3) were filled by the 
Biopolymer loop search facility in Sybyl 7.3 (Tripos, St. Luis, MO) with appropriate 
segments from a binary protein database based on PDB structures. Side chains and 
hydrogens were added using the Biopolymer package of Sybyl 7.3. The models were 
relaxed first with steepest descent minimization using the Amber FF99 force field, 
Amber FF99 charges and a distant dependent dielectric constant of 4, until the RMS 
gradient approaches 0.5 kcal mole-1 Å-1. This initial optimization was followed by a 
Powell minimization (end RMS gradient 0.01 kcal mole-1 Å-1). The energy minimiza-
tions were carried out with fixed backbones to avoid large movements of the TM 
domain (see below). To verify the integrity of the structures, the optimized receptor 
models were submitted to 3D-Verify and Procheck (Luthy et al., 1992). 
Since the N-terminal and the C-terminal segments of the h5-HT2AR are by 39 and 37 
residues, respectively, longer than the corresponding parts of bovine rhodopsin, and 
since the degree of homology is very low in these regions, the modeling of the termini 
is highly speculative. Therefore, the first 70 and the last 71 residues were not con-
sidered in the construction of the models.  
As reference of the inactive state, the h5-HT2AR model derived from the crystal 
structure of bovine rhodopsin (1F88) was used (see Chapter 4). 
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Figure 6.3: Three dimensional models of bovine rhodopsin in the three states of activation. Views are 
from the intracellular site. A. Transition from rhodopsin, inactive state (purple), represented by the 
crystal structure 1F88, to metarhodopsin I380, partially active state (green).  B. Transition from partially 
active state (green) to fully active state (orange) represented by metarhodopsin II.  
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                            10        20        30        40        50   
Rho                mnGtegpnfyVP--------fsnktgvVrsPFeapQyyLae--------- 
h5-HT2A            MDILCEENTSLSSTTNSLMQLNDDTRLYSNDFNSGEANTSDAFNWTVDSE 
 
 
                            60        70        80        90        100  
Rho                --------------------pwqFsmlAayMflLImlGfpiNflTlyVTv 
h5-HT2A            NRTNLSCEGCLSPSCLSLLHLQEKNWSALLTAVVIILTIAGNILVIMAVS 
 
 
                            110       120       130       140       150  
Rho                qHkkLrtplNyILlnLAvADlfMVfgGFtTTLyTSlhGy-FvfgptGÇnl 
h5-HT2A            LEKKLQNATNYFLMSLAIADMLLGFLVMPVSMLTILYGYRWPLPSKLCAV 
 
 
                            160       170       180       190       200  
Rho                EGffATLGGEIaLWSLvvLAieRyvvVckpmsnfrf-genhaimgvafTw 
h5-HT2A            WIYLDVLFSTASIMHLCAISLDRYVAIQNPIHHSRFNSRTKAFLKIIAVW 
 
 
                            210       220       230       240       250  
Rho                vmAlaCAapPlvgwSrYIPEGMQCSÇGIDYYTpheetnNesFViyMfvvH 
h5-HT2A            TISVGISMPIPVFGLQDDSKVFKEGS--------CLLADDNFVLIGSFVS 
 
 
                            260       270       280       290       300  
Rho                fiiPlivIffcygqLvftvkeaaa-------------------------- 
h5-HT2A            FFIPLTIMVITYFLTIKSLQKEATLCVSDLGTRAKLASFSFLPQSSLSSE 
 
 
                            310       320       330       340       350  
Rho                --------------qqqesattqkaekevTrMViiMviAFliCWlpYAgv 
h5-HT2A            KLFQRSIHREPGSYTGRRTMQSISNEQKACKVLGIVFFLFVVMWCPFFIT 
 
 
                            360       370       380       390       400  
Rho                AfyIfthqg---sdFgpifMTipAFfAKtSAVYNPvIYimMnkqFrNCmv 
h5-HT2A            NIMAVICKESCNEDVIGALLNVFVWIGYLSSAVNPLVYTLFNKTYRSAFS 
 
 
                            410       420       430       440       450  
Rho                Ttlccgknplgd-------------------------------------- 
h5-HT2A            RYIQCQYKENKKPLQLILVNTIPALAYKSSQLQMGQKKNSKQDAKTTDND 
 
 
                            460       470        
Rho                -------deasttVsktetsqvapa     
h5-HT2A            CSMVALGKQHSEEASKDNSDGVNEKVSCV 
 
 
Figure 6.4: Sequence alignment of bovine rhodopsin (Rho) with the human 5-HT2A receptor derived 
from the Fugue online server. The amino acids in bold represent the sequences corresponding to the 
α helices in both receptors.  
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6.2.2 Docking of 5-HT2A receptor agonists and partial agonists 
 
Compounds showing different pharmacological profiles, an agonist (5-HT) and a 
partial agonist (cpd. 169), have been docked into the binding site of the models 
representing the active receptor states.. Cpd. 169 belongs to the large series of 5-
HT2AR ligands analysed Chapter 5. The ligands are shown in Figure 6.5.   
The structures were constructed using Sybyl 7.3. All molecules were assumed to be 
protonated under physiological conditions. Amber FF99 atom types and Gasteiger-
Hückel charges were assigned to the ligands. The bioactive conformations were 
derived from the analysis of the binding site of the r5-HT2AR model generated with 
the Fugue/Orchestrar approach (see Chapter 4).  
 
 
 
 
 
 
 
 
 
 
Figure 6.5: Compounds docked into the binding site of 5-HT2A receptor models. 5-HT represents full 
agonists (pEC50 = 7.00, Emax = 100%), and cpd. 169 partial agonists (pEC50 = 6.58, Emax = 49%). 
 
5-HT was docked into the binding site of the fully active form of the h5-HT2AR model 
based on the metarhodopsin II template, and the partial agonist (cpd. 169) into the 
partially active species of the receptor derived from metarhodopsin I380.  
The complexes were optimized using the Amber FF99 force field and agggregates,. 
first constraining the whole and then only the TM backbone to avoid strong 
movements of the relative positions of the seven TM helices. Preliminary studies 
have indicated that such displacements occur without using constraints. Figure 6.6 
compares the starting structure of the fully active receptor with the model after a few 
steps of energy minimization without aggregates. There are significant changes in 
the spatial positions of the TM domains, especially close to the extracellular loops. 
This immoderate effect which is probably due to the more or less arbitrary modeling 
of E2 and E3 by loop searches should not strongly predetermine the resulting 
structure. The same result has been obtained for the partially active 5-HT2AR model.. 
 
HN
NH2
OH
N
H
N
H
N
O
O
OCH3
5-HT Cpd. 169  
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Figure 6.6: Comparison of 
the seven TM domain of the 
starting structure of the active 
state 5-HT2AR model (green) 
with the receptor after some 
steps of minimization without 
aggregates (magenta). View 
from the extracellular side 
 
 
 
 
 
 
 
6.3 Results 
 
6.3.1 Comparison of h5-HT2AR models in different states 
 
The packing of the TM domain in the h5-HT2AR model based on the rhodopsin crystal 
structure shows the typical interactions characterizing the stabilization of the inactive 
state of biogenic amine GPCRs and bovine rhodopsin (Figure 6.7). 
The model suggests that the inactive state is stabilized by several interactions that 
are supposed to be broken during the activation process:  
- a salt bridge formed by two highly conserved amino acids, Arg1733.50 (DRY 
consensus motif in TM3) and Glu3186.30 (cytoplasmic part of TM6),   
- a hydrogen bond network mediating interactions between TM1 (Asn721.50), 
TM2 (Asp1202.50) and TM7 ( Asn3767.49), 
- a disulfide bridge between Cys1483.25 and Cys227E2.15 causing that E2 is 
partially inserted into the transmembrane part, the only interaction that is 
maintained during the activation, 
- a network of intraloop H bonds stabilizing the course of E2, e.g., the backbone 
of Lys220E2.8 is linked with the backbone of Glu224E2.12, Ser226E2.14, and 
Gly225E2.13, the backbone of Asp218E2.6 with the backbone of Leu228E2.16, the 
TM1 
TM2 
TM4 
TM3 
TM7 
TM6 
TM5 
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backbone of Asn233E2.21 with the backbone of Ile2375.41, and the backbone of 
Asp231E2.19 with the backbone of Val2355.39 (Table 6.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7: Interactions stabilizing the inactive state of the h5-HT2AR. A. Hydrogen bond network 
between two amino acids belonging to the DRY sequence (Asp1723.49 and Arg1733.50) and Glu3186.30. 
B. Polar interaction between TM1 (Asn921.50), TM2 (Asp1202.50) and TM7 (Asn3767.49). The red dotted 
lines represent the interaction between residues.  
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            Table 6.1: Conserved intramolecular interactions of the inactive h5-HT2AR state 
 
 
 
 
 
 
 
     
 
  *Distance between the nearest heavy atoms of interacting residues 
 
In the partially active state model, characterized by a lower number of stabilizing H 
bonds, these interactions are not present. The movement of TM3 and TM4 unlocks 
the salt bridge between Arg1733.50 (DRY motif) and Glu3186.30 (I3-TM6 intersection). 
Also the hydrogen bond network between TM1 (Asn721.50), TM2 (Asp1202.50) and 
TM7 ( Asn3767.49) is broken (Figure 6.8). 
Different movements of TM4 (large) and TM5 (small) in their extracellular parts are 
responsible for a conformational change of the second extracellular loop (E2). As 
described for bovine rhodopsin, E2 is partially inserted into the TM domain. This 
insertion is not present in the partially active state (metarhodopsin I380). Furthermore, 
rhodopsin in the dark state and the h5-HT2AR model derived from this template 
contain a β-sheet in E2 that is not present in the partially active structures. The 
second extracellular loop is stabilized in its new conformation by a network of 
intraloop H bonds, e.g. the side chain of Lys220E2.8 is linked with the backbone of 
Asp231E2.19 and the backbone of Leu228E2.16, the backbone of Ser219E2.7 with the 
backbone of Leu228E2.16 and the backbone of Lys223E2.11. However, the recent 
crystal structures of the β2-adrenoceptor in its inactive state (Cherezov et al., 2007; 
Rasmussen et al., 2007) do not confirm the "cap-like" function of E2 but indicate a 
more open conformation allowing easy access of ligands into the TM region (see 
Chapter 5). Therefore, it cannot be concluded that similar conformational changes of 
E2 like suggested in the case of rhodopsin do also play a role for the activation of 
biogenic amine GPCRs.  
Domain Residues Min. distance (Å)* 
TM3 Arg1733.50 - Asp1723.49 2.11 
TM3-TM6 Arg1733.50 - Glu3186.30 1.95 
TM7-TM2 Asn3767.49 - Asp1202.50 2.04 
TM7 Asn3767.49 - Ser3737.46 3.65 
E2-TM5 Glu216E2.4 - Asp2315.35 2.05 
E2 Glu216E2.4 - Asp218E2.6 2.26 
E2 Glu216E2.4 - Leu229E2.17 1.98 
E2 Glu224E2.12 - Lys223E2.11 2.03 
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Figure 6.8: Characteristic regions of the partially active state of the h5-HT2AR deviating from the 
inactive state. Interactions only present in the inactive state – gray dotted lines. The H-bond between 
Asp172 and Arg173 (red dotted line) is conserved in the partially active state. 
 
The last conformational change during the receptor activation is a rotational motion of 
TM6 (see Introduction). In the h5-HT2AR model of the fully active state, this 
movement allows a small rearrangement of the helical segments and the intra- and 
extracellular loops compared to the partially active state. In particular, the E2 loop is 
again inserted into the TM domain and stabilized in this position by a network of 
intraloop H-bond, e.g. the side chain of Lys223E2.11 is linked with the side chain of 
Asp218E2.6 and the backbone of Ser2.19E2.8, the backbone of Glu224E2.12 with the 
backbone of Lys220E2.8. Once more, this rearrangement of E2 seems to be important 
Asp 172
Arg 173
Glu 318 I3
I2
Ser 373
Asn 376
Asp 120
Asn 92
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for rhodopsin activation, but is rather questionable in the case of the h5-HT2AR (see 
above). 
With respect to the putative binding site of the three h5-HT2AR models, an analysis of 
the amino acids interacting with ligands indicates similar binding modes of agonists, 
partial agonists and antagonists. Residues such as Asp1553.32 and Ser1593.36 in TM3, 
Ser2395.43 and Ser2425.46 in TM5 as well as Tyr3707.43 and Trp3677.40 in TM7 are 
similarly oriented in different activation states (Figure 6.9). However, two important 
residues, Phe3396.51 and Phe3406.52, show another orientation in the fully active 
model compared to the models of the inactive and the partially active state. This 
difference is due to the counter-clockwise rotation of TM6 by approximately 100° 
around the axis of the N-terminal TM6 moiety.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.9: Aligned ligand binding sites of the three h5-HT2AR models. Important amino acids are 
drawn in different colours: inactive state – pink, partially active state – cyan, fully active state – green  
The silver ribbon represents the TM helices in the fully active state, and the arrows indicate the 
rotation of TM6.  
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6.3.2 Analysis of the fully active h5-HT2AR model in complex with 5-HT  
 
5-HT was docked into the binding site of the fully active form of the h5-HT2AR model 
derived from metharhodopsin II. Most positions correspond to the 5-HT docking 
mode published previously (Ishiguro et al., 2004). The cationic amine moiety of the 
unsubstituted indole derivatives forms an ionic interaction with Asp1553.32 and an H 
bond with Ser1593.36 (Almaula et al., 1996; Wang et al., 1993). Considering all 
interactions important for the activity of 5-HT, the fit is optimal if a folded conforma-
tion of the ethylamine side chain is assumed (see Figure 6.10). By contrast, 
compounds with a substituent at the cationic amine moiety rather adopt extended 
side chain geometries to enable interactions with hydrophobic residues in TM6 and 
TM7. The indole group was suggested to form H bonds with the two serines 
Ser2395.43 (5-OH substituent) and Ser2425.46 (indole NH) in TM5. Amino acids in 
these two positions are known to be involved in the interaction with neurotransmitters 
in various GPCRs. However, as discussed in Chapters 4 and 5, H bonds of the 
indole NH to the side chains of Ser1593.36 or Thr1603.37 may also be possible since 
Ser2425.46 is mutated into Ala in the rat 5-HT2AR. An interaction of the indole NH with 
the backbone oxygen of Met3356.47, as proposed by Ishiguro et al. (2004), appears to 
be rather uncommon, but cannot be excluded. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.10: Docking of 5-HT into the binding site of the fully active h5-HT2AR model. Ligand – balls 
and sticks, amino acids interacting with 5-HT – sticks only. The red dotted lines represent the polar 
interactions between 5-HT and residues.  
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After energy optimization the key interactions between 5-HT and residues in TM3 
were retained, indicated by the short distances between the charged nitrogen and 
Asp1553.32 (2.49 Å) and Ser1593.36 (2.36 Å), respectively. Remarkably, the indole ring 
is parallel aligned with the side chain of Phe3396.51 indicating optimal π−π interaction. 
This contact is obviously due to the 100° rotation of TM6 in the fully active state and 
replaces the corresponding interaction with Phe3406.52 suggested from docking of 
indole derivatives into the inactive state models and from results with Phe3406.52Leu 
mutants (Choudhary et al., 1993; Roth et al., 1997) (see Chapters 4 and 5). For 
biogenic amine GPCRs it is assumed that the effect of agonists on the so called 
"toggle switch" (Cys3356.47, Trp3366.48 and Phe3406.52 in the case of the 5-HT2AR) 
modulates the proline kink in TM6 (Cherezov et al., 2007; Rosenbaum et al., 2007)  
as precondition for the 100° rotation and, by this, activation of the receptor. Insofar, 
the model in Figure 6.10 could indeed reflect an agonist-bound active GPCR state 
although Phe3396.51Leu mutants do not markedly reduce binding and efficacy of 5-
HT (Choudhary et al., 1993; Roth et al., 1997). The distances of the 5-OH group of 5-
HT and Ser2395.43, and of the indole nitrogen and Ser2425.46 are in the range of 3-3.5 
Å after constrained energy optimization. I.e., the interactions of 5-HT with the 
suggested key residues in TM5 are possibly weaker in the fully active than in the 
inactive state.  
 
6.3.3 Analysis of the partially active h5-HT2AR model in complex with a 
partial agonist  
 
A quinazolinedione derivative (cpd. 169, see Chapters 4 and 5), a partial agonist at 
5-HT2A receptors, was docked into the binding site of the partially active 5-HT2AR 
model based on metarhodopsin I380. The docking pose of the quinazolinedione 
moiety was suggested to be similar to that of the indole moiety in 5-HT. The benzyl 
substituent at the charged nitrogen was assumed to interact with a hydrophobic 
pocket of aromatic residues in TM3, TM6 and TM7 (see Chapter 4). This implies that 
the ethylamine chain adopts an extended conformation. According to the hypothesis 
derived previously (see Chapter 4), the secondary amino group was positioned in 
proximity to the conserved Asp1553.32 in TM3, one of the oxygens and the nitrogen of 
the quinazolinedione ring close to Ser1593.36 and Ser2425.46, respectively, and the 
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second oxygen close to Asn3436.55. A hydrophobic pocket of aromatic residues in 
TM5 (Phe2405.44, Phe2435.47 and Phe2445.48) and TM6 (Phe3406.52) accomodates the 
quinazolinedione moiety. The benzyl substituent is fitted into a second hydrophobic 
pocket, consisting of residues in TM3 (Trp1513.28), TM6 (Trp3366.48 and Phe3396.51), 
and TM7 (Trp3677.40 and Tyr3707.43).  
In the energy optimized model (Figure 6.11), Asp1553.32 is the only residue that inter-
acts with the charged nitrogen. Ser1593.36 is too far away to act as H acceptor and is 
involved in another interaction with one of the oxygens of the quinazolinedione group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.11: Docking of cpd 169 into the binding site of the partially active h5-HT2AR model. Ligand – 
balls and sticks, amino acids interacting with 5-HT – sticks only. A. Polar interactions between 5-HT 
and residues (red dotted lines).  B. Hydrophobic pockets surrounding the ligand (orange). 
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The interaction between the partial agonist and TM3 in the optimized conformation 
does not include only the residues Asp1553.32 and Ser1593.36, but also a hydrophobic 
residue, Tyr1513.28, positioned close to the benzyl substituent of the ligand which also 
interacts with aromatic residues in TM6 and TM7 (see above). The last step in the 
activation process is the rotation of TM6, leading to the different position of 
Phe3396.51 and Phe3406.52 in the partially and the fully active state, respectively. 
These amino acids are involved in the interaction with the agonist (5-HT) and partial 
agonist (cpd. 169), but in a different way. In the fully active model, 5-HT interacts via 
the indole moiety with Phe3396.51, but Phe3406.52 does not approach the ligand. By 
contrast, the partially active model indicates interactions of Phe3396.51 with the benzyl 
and of Phe3406.52 with the quinazolinedione group. Probably the tight fit of the benzyl 
moiety into a hydrophobic pocket containing key residues in TM6 impedes the 
complete receptor activation due to inhibiting the rotation of this helix. I.e, the 
activation energy is higher in the case of partial agonists like cpd. 169, and the 
equilibrium between the partially and the fully active state is shifted to the former one. 
The quinazolinedione moiety interacts with TM5 also in the partially active model. 
The conserved Ser2425.46 is involved in an H bond with one of the oxygens. 
Moreover, a pocket of hydrophobic residues in TM5 (Phe2435.47, Phe2445.48) and 
TM6 (Phe3406.52) inserts the quinazolinedione group. In comparison with the docking 
mode suggested for cpd. 169 at the model of the inactive state relying on the crystal 
structure of bovine rhodopsin (see Chapter 4), the interaction pattern is quite similar 
irrespective of the different positions of TMs 3, 4 and 5. In particular, interactions with 
the hydrophobic pocket formed by residues in TMs 5 and 6 are generally retained. 
This is rather achieved by a global translation and rotation of the ligand together with 
TMs 3 and 5 than by a major conformational change. The quinazolinedione moiety is 
strongly shifted (ca. 5 Å), whereas the benzylamine position differs only by about 
1.5Å when the fixed domains of both models, TMs 1, 2 and 7, are aligned.  
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6.4  Conclusions 
 
Models of the h5-HT2AR in different activation states suggest conformational 
differences and important collective changes of TM domains during the activation 
process. These models also help in understanding the different interactions of typical 
agonists and partial agonists with a largely common binding site. The analysis of the 
putative receptor-ligand interactions has shown that: 
- The different 5-HT2AR states are similar with respect to the amino acids 
interacting with ligands, but show individual topologies of the binding sites due 
to TM movements. The interconversion of states may be accompanied by co-
translations and rotations of the ligands. 
- Rather weak interactions with residues in TM5 of the fully active 5-HT2AR state 
are possibly one of the reasons for the low activity of 5-HT.  
- The binding site of the partially active 5-HT2AR model accomodates the partial 
agonist 169 by polar and hydrophobic interactions. Probably the tight fit of the 
benzyl substituent into a hydrophobic pocket containing key residues in TM6 
impedes the complete receptor activation due to inhibiting the rotation of this 
helix  
Generally, the inhibition of collective TM moves may be a common principle by 
which partial agonists and antagonists "act" unlike agonists. Interactions with 
additional binding sites lead to stabilized, more rigid conformational states of the 
complex requiring high activation energies to convert into other states. In 
particular, more or less stabilization of the "toggle switch region" in TM6 will 
determine the efficacy of a ligand. High affinity of a partial agonist or antagonist is 
therefore at the expense of its ability to activate a receptor. 
Although the present results on h5-HT2AR states and their interactions with 
ligands are only derived from putative models of rhodopsin states, general 
insights into possible activation modes of GPCRs have been obtained which may 
help in deriving refined models on the base of experimental receptor structures. 
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7 Pippo 
 
Chapter 7 
Summary 
 
The 5-HT2A receptor (5-HT2AR) is a biogenic amine receptor that belongs to the class 
A of G protein coupled receptors. It is characterized by a low affinity for serotonin (5-
HT) and for other primary amines. Introduction of an ortho-methoxybenzyl substituent 
at the amine nitrogen increases the partial agonistic activity by a factor of 40 to 1400 
compared with 5-HT.  
The present study was to analyse the QSAR of a series of 51 5-HT2AR partial 
agonistic arylethylamines, tested in vascular in-vitro assays on rats, at a structure-
based level and to suggest ligand binding sites. The compounds belong to three 
different structural classes, (1) indoles, (2) methoxybenzenes (including benzo-
difurans as cyclic analogs) and (3) quinazolinediones. Following a hierarchical 
strategy, different methods have been applied which all contribute to the investigation 
of ligand-receptor interactions: fragment regression analysis (FRA), receptor 
modeling, docking studies and 3D QSAR approaches (comparative molecular field 
analysis, CoMFA, and comparative molecular similarity index analysis, CoMSIA). 
An initial FRA indicated that methoxy substituents at indole and phenyl derivatives 
increase the activity and may be involved in polar interactions with the 5-HT2AR. The 
large contribution of lipophilic substituents in p position of phenethylamines suggests 
fit to a specific hydrophobic pocket. Secondary benzylamines are more than one 
order of magnitude more active than their NH2 analogs. An ortho-OH or -OMe 
substituent at the benzyl moiety further increases activity. 
Homology models of the human and rat 5-HT2AR were generated using the crystal 
structure of bovine rhodopsin and of the β2-adrenoceptor as templates. The 
derivation of the putative binding sites for the arylethylamines was based on the 
results from FRA and on mutagenesis data. Both templates led to 5-HT2AR models 
with similar topology of the binding pocket within the transmembrane domains TM3, 
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TM5, TM6 and TM7. Docking studies with representative members of the three 
structural classes of partial agonists suggested that the aryl moieties and particularly 
para-substituents in phenyl derivatives fit into a hydrophobic pocket formed by 
Phe2435.47, Phe2445.48 and Phe3406.52. The 5-methoxy substituents in indole and 
phenyl compounds form H bonds with Ser2395.43. In each case, an additional H bond 
with Ser1593.36 may be assumed. The cationic amine interacts with the conserved 
Asp1553.32. The benzyl group of secondary arylethylamines is inserted into another 
hydrophobic pocket formed by Phe3396.51, Trp3677.40 and Tyr3707.43. In this region, 
the docking poses depend on the template used for model generation, leading to 
different interactions especially of ortho- substituents. 
The docking studies with the β2-adrenoceptor based rat 5-HT2AR model provided 
templates for a structure-based alignment of the whole series which was used in 3D 
QSAR analyses of the partial agonistic activity. Both approaches, CoMFA and 
CoMSIA, led to highly predictive models with low complexity (cross-validated q2 of 
0.72 and 0.81 at 4 and 3 components, respectively). The results were largely 
compatible with the binding site and confirm the docking studies and the suggested 
ligand-receptor interactions. Steric and hydrophobic field effects on the potency 
indicate a hydrophobic pocket around the aryl moiety and near the para position of 
phenyl derivatives and account for the increased activity of secondary benzylamines. 
The effects of electrostatic and H-bond acceptor fields suggest a favourable influence 
of negative charges around the aryl moiety, corresponding to the increase in potency 
caused by methoxy substituents in 2-, 4-, 5- and 6-position of phenethylamines and 
by the quinazolinedione oxygens. This is in accord with the role of Ser1593.36 and 
Ser2395.43 as H bond donors. At the benzyl moiety, the negative charge and the 
acceptor potential of, in particular, 2-hydroxy and -methoxy substituents is of 
advantage. 
Partial and full agonists stabilize or induce active receptor states not reflected by the 
existing crystal structures. Based on models of different rhodopsin states, a homo-
logy modeling and ligand docking study on corresponding 5-HT2AR states suggested 
to be specific to agonist and partial agonist binding, respectively, was performed. The 
models indicate collective conformational changes of TM domains during activation. 
The different 5-HT2AR states are similar with respect to the amino acids interacting 
with the arylethylamines, but show individual topologies of the binding sites. The 
interconversion of states by TM movements may be accompanied by co-translations 
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and rotations of the ligands. In the case of the secondary amines considered, the 
tight fit of the benzyl substituent into a hydrophobic pocket containing key residues in 
TM6 probably impedes the complete receptor activation due to inhibiting the rotation 
of this helix. High affinity of a partial agonist is therefore often at the expense of its 
ability to fully activate a receptor. 
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Chapter 8 
Appendix 
 
8.1 Abbreviations 
 
3D    three-dimensional 
5HT    5-hydroxytryptamine, serotonin 
5-HTR   serotonergic receptor, 5-HT receptor 
CNS    central nervous system  
CoMFA   comparative molecular field analysis 
CoMSIA   comparative molecular similarity index analysis 
DAG    diacylglycerol 
DOB    1-(4-bromo-2,5-dimethoxyphenyl)-isopropylamine 
DOI    1-(4-iodo-2,5-dimethoxyphenyl)-isopropylamine 
DMT    dimethyltryptamine 
E1, E2, E3 1st, 2nd, and 3rd extracellular loop of G protein coupled 
receptors 
EC50    agonist concentration inducing 50% of the maximum effect 
ER    endoplasmatic reticulum 
FRA    fragment regression analysis 
Gα    α-subunit of G proteins 
Gβγ    heterodimer formed by β and γ subunits of G proteins 
GDP    guanosine diphosphate 
GPCR   G protein coupled receptor 
GTP    guanosine threephosphate 
h5-HT2AR   human serotonergic 2A receptor 
I1, I2, I3 1st, 2nd, and 3rd intracellular loop of G protein coupled 
receptors 
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IP3    Inositolthreephosphate 
LSD    Lysergic acid diethylamide 
PC    principal component 
PDB    protein data bank 
PKC    protein kinase C 
PLC    phospholipase C 
PLS    partial least squares  
QSAR    quantitative structure-activity relationships 
r5-HT2AR   rat serotonergic 2A receptor 
RMSD   root mean square deviation 
SAR    structure-activity relationships 
TM    transmembrane domain of G protein coupled receptors 
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